NCTId,Title,Condition,Status,Eligibility,Phase,Enrollment,StudyType
NCT00188617,Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC,LUNG CANCER,COMPLETED,"Inclusion Criteria:

* Patients must have biopsy-proven non-small cell lung carcinoma (NSCLC) or a lung nodule seen on CT imaging and a high-clinical suspicion of NSCLC
* Clinical Stage 1A (T1N0M0 a tumor that is 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus)
* or 1B (T2N0M0 a tumor with any of the following features of size or extent: More than 3 cm in greatest dimension. Involves the main bronchus, 2 cm or more distal to the carina. Invades the visceral pleura. Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung).

  * Must be deemed appropriate surgical candidate
  * ECOG performance status £ 2
  * Age ³ 18 years
  * No prior chemotherapy, radiotherapy or EGFR inhibitors
  * Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Patients who have received prior anticancer treatment with chemotherapy, radiotherapy or EGFR inhibitor therapy;
* Patients who have had a previous diagnosis of cancer, are excluded except if have been adequately treated for non-melanoma skin cancer or carcinoma in situ of the cervix are eligible irrespective of when that treatment was given.
* Patients may not be receiving any other investigational or anticancer agents while on study;
* History of allergic reactions to Gefitinib or erlotinib
* Pre-existing diarrhea ³ NCI CTC Grade 2
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure or evidence of cardiac dysfunction, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease, poorly controlled diabetes mellitus, clinically significant or untreated ophthalmologic (e.g. Sjogrens etc.) or gastrointestinal conditions (e.g. Crohns disease, ulcerative colitis) or psychiatric illness/social situations that would limit compliance with study requirements.
* Pregnant women because of the unknown effects of Gefitinib on the human fetus.
* HIV-positive patients on active treatment
* Active malignancy at any other site including combined small cell and non-small cell carcinomas or a pulmonary carcinoid tumor.
* Taking drugs that induce CYP3A4 enzymes, patients with ongoing use of phenytoin, rifampicin, carbamazepine, barbiturates, rifampicin, or St John's Wort are excluded.
* Incomplete healing from previous surgery.
* Use of any agent that decreases gastric pH, including proton pump inhibitors, Histamine-2 receptor blockers or sodium bicarbonate. Use of calcium or magnesium based elixirs are not included.",,,INTERVENTIONAL
NCT00005806,Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer,Lung Cancer,COMPLETED,"DISEASE CHARACTERISTICS: Histologically and/or cytologically confirmed advanced or metastatic non-small cell lung cancer considered incurable with standard surgery or irradiation No active brain metastases as indicated by clinical symptoms, cerebral edema, and/or progressive growth

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-1 that has not worsened within the past 7 days Life expectancy: At least 12 weeks Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.25 times upper limit of normal (ULN) ALT/AST no greater than 2.5 times ULN (5 times ULN if liver metastases) Renal: Creatinine no greater than 1.25 times ULN No greater than a trace of blood or protein on urine labstix test Cardiovascular: No prior history of clinically significant cardiac dysrhythmia, first degree heart block, or other severe cardiac disease Opthalmologic: No potentially visually threatening epithelial abnormality of the cornea other than scars, congenital abnormality, or corneal tear film (e.g., neurotrophic keratitis, corneal edema, or recurrent erosions) No signs and symptoms of keratoconjunctivitis sicca No concurrent use of contact lenses Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other malignancies within the past 5 years except basal cell carcinoma or carcinoma in situ of the cervix No evidence of severe or uncontrolled systemic diseases (e.g., hepatitis B, hepatitis C, or HIV) No known chronic conditions No active dermatoses involving the face No evidence of any other significant clinical disorder or laboratory finding that would preclude study participation

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy for non-small cell lung cancer No concurrent biologic response modifiers Concurrent filgrastim (G-CSF) allowed only for persistent neutropenia despite dose reductions in prior course Chemotherapy: No prior chemotherapy for non-small cell lung cancer Endocrine therapy: No concurrent hormonal therapy No concurrent tamoxifen Radiotherapy: See Disease Characteristics At least 2 weeks since prior radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics Recovered from prior oncologic or other major surgery Other: No other concurrent anticancer therapy No other concurrent investigational agents No concurrent drugs with known significant 3A4 inhibitory effects (i.e., ketoconazole, itraconazole, troleandomycin, erythromycin, diltiazem, verapamil) No concurrent hydroxychloroquine, amiodarone, or chlorpromazine No concurrent topical eye medication",,,INTERVENTIONAL
NCT02863055,Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma,Malignant Pleural Mesothelioma,ACTIVE_NOT_RECRUITING,"Inclusion Criteria:

* Histological diagnosis of unresectable Malignant Pleural Mesothelioma (MPM);
* Response or Stable disease according to modified RECIST criteria \[48\] after first line platinum-pemetrexed chemotherapy for 4-6 cycles;
* Last platinum chemotherapy dose administered within 60 days (i.e. randomization must occur within 60 days from the last dose of the last cycle of platinum-pemetrexed chemotherapy);
* Age \>18 years;
* ECOG performance status (PS) 0-2;
* Life expectancy of at least 12 weeks in the opinion of the investigator;
* Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of first dose

Exclusion Criteria:

* prior systemic anticancer therapy including cytotoxic therapy or immune-checkpoint inhibitor, for MPM, other than first line platinum-based doublet chemotherapy;
* previous extra-pleural pneumonectomy (other forms of previous surgery eg pleurectomy are acceptable);
* previous Vascular Endothelial Growth Factor (VEGF) inhibitors (eg bevacizumab, sorafenib, etc);
* treatment with other investigational drugs or treatment in another clinical interventional trial within the past 4 weeks before start of therapy or concomitantly with the trial;
* patients that, in the opinion of the investigator, have reduced performance status by 2 ECOG levels (e.g. PS 0 to 2 or PS 1 to 3) from beginning to completion of 1st line chemotherapy;
* radiotherapy (with the exception of palliative radiotherapy) during study or within 4 weeks of start of study drug;
* known brain metastasis or lepto-meningeal disease. Patients with suspicious neurological symptoms should undergo a CT scan/MRI of the brain to exclude brain metastasisNo active brain metastases (e.g. stable for \< 4 weeks;, no adequate previous treatment with radiotherapy;, symptomatic, requiring treatment with anti-convulsants; dexamethasone therapy will be allowed if administered as stable dose for at least one month before randomization); patients with suspicious neurological symptoms should undergo a CT scan/MRI of the brain to assess brain metastasis;
* leptomeningeal metastases;
* significant weight loss (\> 10 %) within the past 6 weeks prior to treatment in the present trial;
* pre-existing clinically significant ascites and/or clinically significant pleural effusion;
* active or history of bleeding complications that would prevent anti-angiogenic therapy
* centrally located tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels; typical mediastinal pleural involvement with mesothelioma remains eligible;
* clinically active cancer other than mesothelioma within 5 years prior to start of study treatment;
* radiographic evidence of cavitatory or necrotic tumors;
* unstoppable use of therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic acid =325mg per day);
* clinically significant cardiovascular diseases (i.e. hypertension not controlled by medical therapy, unstable angina, history of myocardial infarction within the past 6 months, congestive New York Heart Association (NYHA) II, serious cardiac arrhythmia, clinically significant pericardial effusion)",,,INTERVENTIONAL
NCT05032352,Predictive Assay for Decision Making in Adjuvant Therapy,"Carcinoma, Non-Small-Cell Lung",TERMINATED,"Inclusion Criteria:

1. Written informed consent using the appropriate approved Institutional Review Board (IRB) approved consent.
2. Age ≥ 18 years
3. Able to comply with the protocol, including acceptable candidacy for adjuvant chemotherapy and likely compliance with follow-up for anticipated length of study (18 months from randomization).
4. Adequate tissue sample, paraffin block with tumor occupying at least 25% of the tissue surface area, for the 14 -gene prognostic assay, DetermaRx
5. Histologically documented completely resected (R0) Stage I or IIA non-squamous NSCLC per 8th edition, TNM staging system. Mixed histology cases (adenosquamous), large cell, or adenocarcinoma not otherwise classified (NOS) are eligible for the study, as long as they contain at least some component that is neither squamous cell, nor small cell nor neuroendocrine. Eligible resections include lobectomy, bilobectomy, segmentectomy, sleeve lobectomy and pneumonectomy. Resections via segmentectomy or wedge resection should be limited to patients with a peripheral tumor 2 cm or less with wide margins (\> 2 cm or \> the size of the nodule). Complete resection must also be accompanied, at a minimum, by intra-operative systematic mediastinal lymph node sampling. Systematic sampling is defined as removal of at least one representative lymph node each from levels 4 and 7 for a right-sided cancer and from levels 5 and/or 6 and 7 for left-sided cancers. Complete mediastinal lymph node dissection (MLND), however, is preferred, and is defined as resection of all lymph nodes at those same levels for right- and left-sided cancers.
6. ECOG performance status 0-1
7. No prior anti-neoplastic (NSCLC ) treatment in the pre-operative or post-operative setting (including chemotherapy, targeted therapy, immunotherapy, radiation, ablative procedures, etc.)

Exclusion Criteria:

1. Final pathologic diagnosis of pure squamous cell, pure small cell, or pure neuroendocrine histology, or any combination of only these three histological subtypes.
2. Evidence of greater than stage IIA pathologic staging
3. Evidence of incomplete resection (R1)
4. Prior systemic chemotherapy or anti-cancer agent for NSCLC
5. Any pre- or post-operative radiotherapy for the index tumor being considered for enrollment",,,OBSERVATIONAL
NCT06557967,Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment,"Non-small Cell Lung Cancer, Lung Cancer, Metastatic Cancer, Brain and Central Nervous System Cancer",COMPLETED,"Inclusion Criteria:

1. Diagnosis of mNSCLC in study period (01/01/2015-06/30/2023) including newly diagnosed at metastatic stage or progression from advanced stage NSCLC
2. Age 18+ years at the time of diagnosis of mNSCLC

   Additional inclusion criteria for 1st Line of Therapy cohort:
3. Treated with systemic anti-cancer therapy in 1L setting

   Additional inclusion criteria for 2nd Line of Therapy and 3rd Line of Therapy cohorts:
4. Treated with systemic anti-cancer therapy in 2L setting treated with systemic anti-cancer therapy in 3L setting

Exclusion Criteria:

1. Evidence of other primary malignancy in the 365-day baseline period immediately prior to the first mNSCLC diagnosis in the study period
2. Evidence of stereotactic radiosurgery (SRS), stereotactic radiation therapy (SRT), or whole brain radiotherapy (WBRT) in the baseline period",,,OBSERVATIONAL
NCT07014202,Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy,Non-Small Cell Lung Cancer,RECRUITING,"Inclusion Criteria:

1. Voluntary signed written informed consent and compliance with protocol requirements;
2. Age ≥ 18 years;
3. Expected survival time ≥ 3 months;
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
5. Histologically or cytologically confirmed advanced non-small cell lung cancer;
6. After receiving 4-6 cycles of first-line platinum-based chemotherapy combined with immunotherapy, PET-CT evaluation shows no disease progression, with no more than 5 lesions not meeting criteria for complete metabolic response, involving no more than 3 organs;
7. All residual lesions can safely receive radiation therapy as assessed by radiation oncologists;
8. Patient can tolerate the radiotherapy process, such as maintaining fixed position;
9. At least one measurable lesion among the oligoresidual lesions according to RECIST v1.1;
10. Agreement to provide archived tumor tissue specimens from primary or metastatic sites, or fresh tissue samples; if unable to provide tumor tissue samples, subjects may be enrolled after investigator assessment if meeting other inclusion/exclusion criteria;
11. Toxicities from previous anti-tumor therapies recovered to ≤ grade 1 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0) (excluding alopecia, fatigue, pigmentation, hypothyroidism stable on hormone replacement therapy, grade 2 peripheral neuropathy after chemotherapy, and exceptions specified in other inclusion criteria);
12. Laboratory values at screening must meet the following criteria: a) Neutrophils ≥ 1.5×10\^9/L b) Platelets ≥ 100×10\^9/L c) Hemoglobin ≥ 90g/L (no blood transfusion within 14 days) d) Serum Cr ≤ 1×ULN, endogenous creatinine clearance \> 50ml/min (Cockcroft-Gault formula) e) AST ≤ 2.5×ULN; ALT ≤ 2.5×ULN; if liver metastases present, ALT and AST ≤ 5×ULN f) Total bilirubin ≤ 1.5×ULN (except for Gilbert's syndrome subjects, where total bilirubin must be \< 51.3μmol/L) g) Thyroid Stimulating Hormone (TSH), Free Triiodothyronine (FT3), Free Thyroxine (FT4) all within ±10% of normal range.

Exclusion Criteria:

1. Archived tumor tissue, pre-treatment tumor biopsy, or histological examination showing evidence of previous small cell or mixed small cell/non-small cell histology;
2. Previous tissue samples or peripheral blood genetic sequencing reports indicating EGFR sensitizing mutations, ALK fusion, or other gene variations that should receive standard first-line targeted therapy; squamous cell carcinoma without genetic testing is presumed negative;
3. Symptomatic brain metastases;
4. Leptomeningeal metastases;
5. Active, known, or suspected autoimmune disease (excluding vitiligo, type I diabetes, residual hypothyroidism due to autoimmune thyroiditis requiring only hormone replacement therapy, or conditions not expected to recur in the absence of external triggers);
6. Active tuberculosis (TB) infection as determined by chest X-ray, sputum examination, and clinical examination. Patients with a history of active pulmonary TB infection within the previous year, even if treated, will be excluded. Patients with a history of active pulmonary TB infection more than 1 year ago will also be excluded unless effective previous anti-TB treatment can be documented;
7. Comorbidities requiring immunosuppressive medication, or requiring systemic or local use of corticosteroids at immunosuppressive doses;
8. Pregnancy or breastfeeding;
9. Interstitial lung disease with symptomatic manifestations, or that may interfere with the detection or management of suspected drug-related pulmonary toxicity;
10. Positive for human immunodeficiency virus antibody (HIVAb), active hepatitis B virus infection (HBsAg positive and HBV-DNA \> 10\^3 copies/ml), or hepatitis C virus infection (HCV antibody positive and HCV-RNA \> lower limit of detection at the research center);
11. History of severe neurological or psychiatric disorders, including but not limited to: dementia, depression, seizures, bipolar disorder, etc.;
12. Receipt of other investigational drugs or treatments within 4 weeks prior to study randomization;
13. Use of any Chinese herbal medicines with anti-tumor activity within 2 weeks prior to study drug administration;
14. History of other malignancies (excluding non-melanoma skin cancer and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast), unless complete remission was achieved at least 2 years prior to study enrollment and no additional therapy is required or anticipated during the study period;
15. History of severe cardiac or cerebrovascular disease, e.g., New York Heart Association (NYHA) ≥ class 2 heart failure, acute coronary syndrome (such as myocardial infarction, unstable angina, etc.) within 6 months of screening, acute cerebrovascular disease (such as transient ischemic attack, cerebral infarction, cerebral hemorrhage, etc.) within 6 months of screening;
16. Thromboembolic events requiring therapeutic intervention within 6 months prior to screening, such as unstable deep vein thrombosis, arterial thrombosis, and pulmonary embolism; excluding infusion-related thrombosis;
17. Planned vaccination or vaccination with live vaccines within 28 days prior to study randomization;
18. Other conditions deemed unsuitable for participation in this clinical trial by the investigator due to comorbidities or other circumstances.",,,INTERVENTIONAL
NCT06581419,A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors,"Advanced Malignant Neoplasm, Advanced or Metastatic Non-small Cell Lung Cancer",RECRUITING,"Inclusion Criteria:

1. Age of 18-75 years old (including cut-off value), regardless of gender.
2. Phase I only: patients with histologically confirmed advanced or metastatic malignant solid tumors who have failed to respond to standard treatment, who have no standard treatment options, who are not currently applicable to standard treatment, or who have been assessed by the investigator to benefit from this treatment.
3. Phase II only: patients with histologically confirmed locally advanced (stage IIIB or IIIC) or metastatic (stage IV) non-small cell lung cancer (NSCLC) that is not amenable to complete surgical resection and definitive concurrent chemoradiotherapy. Note: For patients with locally advanced stage (stage IIIB/IIIC) who cannot accept radical concurrent/sequential chemoradiotherapy, they need to be evaluated by relevant professional physicians and confirmed by written records.
4. Phase II only: no prior systemic antitumor therapy for locally advanced or metastatic NSCLC (except for patients who received adjuvant/neoadjuvant chemotherapy or definitive concurrent or sequential chemoradiotherapy for locally advanced disease and disease progression ≥6 months after the last treatment).
5. Phase II only: PD-L1 positive (TPS≥50%) as determined by IHC, and patients were negative for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) by immunohistochemistry.
6. have at least one measurable lesion according to RECIST 1.1 criteria (tumor lesion located in the previous radiotherapy area or other locoregional treatment site, generally not considered a measurable lesion unless the lesion has clearly progressed or persists beyond three months of radiotherapy).
7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
8. predicted survival time ≥3 months.
9. with adequate organ function:

   ① Blood system (no blood transfusion or hematopoietic stimulation therapy within 14 days) : absolute neutrophil count (ANC) ≥1.5×109/L, platelet count (PLT) ≥100×109/L, hemoglobin (HGB) ≥90 g/L; ② Liver function: total bilirubin (TBIL) ≤1.5 times the upper limit of normal value (ULN), except Gilbert's syndrome Out of; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 times ULN, and patients with liver metastasis or liver cancer need AST and ALT≤5.0 times ULN and total bilirubin ≤3.0 times ULN;

   ② Renal function: serum creatinine (Cr) ≤1.5 times ULN; If creatinine \> 1.5 times ULN, creatinine clearance (Ccr) ≥50 mL/min (calculated by Cockcroft-Gault formula) was required.

   ③ Coagulation function: prothrombin international normalized ratio (INR) ≤1.5 times ULN, activated partial thromboplastin time (APTT) ≤1.5 times ULN, patients with liver metastasis or liver cancer need INR and APTT≤2.5 times ULN.
10. Eligible patients (men and women) of childbearing potential must consent to use a reliable method of contraception (hormonal or barrier methods or abstinence) with their partner during the trial and for at least 6 months after the last dose; Female patients of reproductive age had to have a negative blood pregnancy test within 7 days before the first use of the study drug.
11. Subjects must give informed consent for this study and voluntarily provide written informed consent before the trial.

Exclusion Criteria:

1. Phase II only: small cell lung cancer or sarcomatoid lesion confirmed by histopathology.
2. Phase II only: previous immunotherapy, including immune checkpoint inhibitors (e.g., anti-PD-1 /PD-L1 antibody, anti-CTLA-4 antibody, etc.), immune checkpoint agonists (e.g. ICOS, CD40, CD137, GITR, OX40 antibody, etc.), immune cell therapy, and any treatment targeting the mechanism of tumor immune action.
3. Phase I only: patients received anti-tumor therapy such as systemic chemotherapy, radiotherapy, biological therapy, endocrine therapy, or immunotherapy within 4 weeks before the first dose of study drug; The following drugs were excluded according to the following criteria:

   ① Treatment with a small-molecule tyrosine kinase inhibitor within 2 weeks before the first dose;

   ② Palliative local treatment for non-target lesions within 2 weeks before the first dose; Patients received non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, not including IL-11) within 2 weeks before the first dose;

   ③ received Chinese herbal medicine or Chinese patent medicine with anti-tumor indications within 2 weeks before the first dose.
4. received other investigational drugs or treatments within 4 weeks before the study drug.
5. received systemic glucocorticoids (prednisone \> 10 mg/ day or equivalent) or other immunosuppressive agents within 14 days before the first dose of study drug; The use of topical, ocular, intra-articular, nasal, and inhaled glucocorticoids was excluded. Short-term prophylaxis with glucocorticoids (e.g., to prevent contrast allergy).
6. the adverse effects of previous antineoplastic therapy have not recovered to CTCAE 5.0 grade ≤1 or the relevant requirements of the inclusion criteria (except for toxicities without safety risks judged by the investigators, such as alopecia, grade 2 peripheral neurotoxicity, and hypothyroidism stable with hormone replacement therapy).
7. major surgical procedures (excluding needle biopsies) within 4 weeks before the first dose of study drug, major trauma, or the need for elective surgery during the trial.
8. prior allogeneic hematopoietic stem-cell transplantation or organ transplantation.
9. clinically symptomatic parenchymal or meningeal metastases.
10. have active infection and currently require intravenous anti-infective therapy.
11. have a history of immunodeficiency, including testing positive for human immunodeficiency virus (HIV) antibodies.
12. active hepatitis B (HBsAg positive and HBV-DNA positive or greater than the upper limit of normal), active hepatitis C (hepatitis C virus antibody positive and HCV RNA positive or greater than the upper limit of normal).
13. received any live vaccine within 4 weeks before the first dose of study drug.
14. known hypersensitivity to any antibody-based drug (NCI CTCAE grade 5.0 ≥3) or to the study drug, active ingredient, or inactive excipients of a PD-1/PD-L1 inhibitor.
15. with severe and uncontrollable lung diseases (severe infectious pneumonia, interstitial lung disease, etc.); Or other moderate-to-severe lung diseases that severely affect respiratory function that may interfere with the detection or management of drug-related pulmonary toxicity.
16. have a history of severe cardiovascular and cerebrovascular disease, including but not limited to:

    ① Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia requiring clinical intervention, II-III degree atrioventricular block, etc.

    ② Mean QT interval corrected with Fridericia's method (QTcF) \> 470 ms;

    ③ Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other grade 3 or above cardiovascular and cerebrovascular events occurred within 6 months before the first dose; ④ patients with New York Heart Association (NYHA) functional class ≥II heart failure or left ventricular ejection fraction (LVEF) \< 50% or structural heart disease with high risk as judged by other investigators; And 5) clinically uncontrolled hypertension.
17. have an active or previous autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.) with the possibility of recurrence, except clinically stable autoimmune thyroid disease, type I diabetes mellitus, vitiligo, cured atopic dermatitis in children, and psoriasis (within the past 2 years) that does not require systemic treatment.""
18. had other malignancies within 5 years before study administration, except for malignancies that could be expected to be cured with treatment (including, but not limited to, adequately treated thyroid cancer, carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated with radical surgery).
19. have clinically uncontrollable effusion in the third space, which was judged by the investigator to be not suitable for enrollment.
20. known alcohol or drug dependence.
21. with mental disorders or poor adherence.
22. pregnant or lactating women.
23. The participant was deemed by the investigator to have a history of other serious systemic diseases or to be ineligible for the study for other reasons.",,,INTERVENTIONAL
NCT00043823,Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer,Lung Cancer,COMPLETED,"Inclusion Criteria:

* Patient has histologically proven stage IIIB with pleural effusion, stage IV or recurrent non-squamous NSCLC.
* Patient has a Karnofsky performance status \>=70%.
* Patient has adequate bone marrow function: WBC \>= 3,000 cells/mm3, ANC \>= 1,500 cells/mm3, platelet count \>= 100,000 cells/mm3, Hgb \>= 9.0 g/dL.
* Patient has adequate liver function: total bilirubin level \<= 2.0 mg/dL, albumin \>= 2.5 g/dL.
* Transaminases (aspartate aminotransferase (AST or SGOT) and/or alanine aminotransferase (ALT or SGPT)) and alkaline phosphatase may be up to 2.5 x ULN.
* Patient has adequate renal function: a serum creatinine \< 2 mg/dl
* Patient has signed a written informed consent.
* Patient has received at least one prior chemotherapeutic regimen for recurrent or metastatic disease.

Exclusion Criteria:

* Patient has not received prior chemotherapeutic regimens for advanced disease.
* Patient has received prior biologic therapy targeting epidermal growth factor receptor (EGFR) and/or Vascular endothelial growth factor (VEGF).
* Patient has received radiation therapy within the past 3 weeks.
* Patient has signs or symptoms of acute infection requiring systemic therapy.
* Patient exhibits confusion, disorientation, or has a history of major psychiatric illness that may impair patient's understanding of the informed consent.
* Patient requires total parenteral nutrition with lipids.
* Patient has a history of uncontrolled heart disease and/or uncontrolled hypertension (\> 150/100 mmHg).
* Because of the possible teratogenic effect, pregnant women and women who are currently breast-feeding may not participate in this study. - All women of childbearing potential must have a negative pregnancy test within 24 hours prior to enrolling in the study.
* Serious infection or other intercurrent illness requiring immediate therapy.
* Clinical/imaging evidence of Central Nervous System (CNS) malignancy or with recently treated CNS malignancy, as well as those experiencing recent cerebrovascular accident (CVA), or other CNS bleeding.
* Pediatric patients in whom open growth plates would be expected.
* Urine protein qualitative value of \> 30 in urinalysis or \> +1 in proteinuria testing by dipstick.
* Patient has a clinical history of coagulopathy or thrombosis.
* Patient is currently receiving or intending to receive anti-coagulants.
* Patient has had a recent myocardial infarction (still inside the healing period). Note: a six-month window is optimal.
* Patient is recovering from recent major surgery (e.g., less than 2 weeks since surgery) or is anticipating major surgery.
* Patient has a clinical history of hemoptysis or hematemesis.
* Patient may not have percutaneous endoscopic gastrostomy (PEG) or gastrostomy (G) tube.",,,INTERVENTIONAL
NCT06921681,Ultrasound-guided Cryobiopsy of Mediastinal/Hilar Lymph Nodes,Lung Cancer (NSCLC),RECRUITING,"Inclusion Criteria:

* At least one mediastinal lesion or hilar 1 cm or longer in the short axis requiring diagnostic bronchoscopy
* Age between 18 and 90 years
* Written informed consent after participant's information

Exclusion Criteria:

* Age \< 18 and \> 90 years
* Lacking ability to form an informed consent (including impaired judgement, communication barriers)
* Contraindication against bronchoscopy (e.g. co-morbidities)
* Mediastinal abscess or cyst
* Extraordinary blood supply of the lesion visualized by EBUS bronchoscope
* INR \> 1.5 or Thrombocytes \< 100 G/l
* Clopidogrel or other new antiplatelet drugs within 7 days before biopsy (salicylic acid alone allowed)
* Anticoagulation with NOAC within 48 hours before biopsy
* Pulmonary lesions suspicious of lung carcinoma",,,INTERVENTIONAL
NCT05698238,Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours,"Clear Cell Renal Cell Carcinoma Metastatic, TNBC - Triple-Negative Breast Cancer, Head and Neck Cancer, Non-small-cell Lung Carcinoma, Mesothelioma, Malignant",NOT_YET_RECRUITING,"Inclusion Criteria:

* Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up
* Histologically proven solid tumors (Clear Cell Renal Cell Carcinoma Metastatic, Triple-Negative Breast Cancer, Head and Neck Cancer, Non-small-cell Lung Carcinoma, Malignant Mesothelioma) refractory to conventional treatment, or for which no conventional therapy is considered appropriate by the Investigator or is declined by the patient
* Life expectancy of at least 12 weeks
* World Health Organization (WHO) performance status of 0 or 1
* Hematological and biochemical indices within the ranges (hemoglobin ≥9.0 g/dL, absolute neutrophil count ≥1.5 x 109/L, platelet count ≥100 x 109/L, bilirubin ≤1.5 x upper limit of normal, alanine amino-transferase (ALT) and aspartate amino-transferase (AST) ≤ 2.5 x upper limit of normal. These measurements must be performed within one week (Day -7 to Day -1) before the patient receives their first infusion of CA9hi-1.
* Calculated creatinine clearance or isotope clearance measurement ≥ 50 mL/min
* PT/APTT ≤1.5 upper limit of normal

Exclusion Criteria:

* Ongoing toxic manifestations of previous treatments (Grade 2 or greater according to NCI-CTCAE v4.02) with the exception of alopecia or certain Grade 2 toxicities, which in the opinion of the investigator and CDD should not exclude the patient - these should be discussed on a case by case basis
* Symptomatic brain metastases or spinal cord compression
* Patients who have received prior radiotherapy to their lungs will not be eligible for this trial.
* Female patients who are able to become pregnant (or already pregnant or lactating). However, those patients who have a negative serum or urine pregnancy test before enrolment and agree to use two highly effective forms of contraception (oral; injected or implanted hormonal contraception and condom; have an intra-uterine device and condom; diaphragm with spermicidal gel and condom) effective at the first administration of CA9hu-1, throughout the trial and for six months afterwards are considered eligible. Breast feeding should be discontinued if the mother is treated with CA9hu-1.
* Male patients with partners of child-bearing potential (unless they agree to take measures not to father children by using one form of highly effective contraception \[condom plus spermicide\] effective at the first administration of hu-CA91, throughout the trial and for six months afterwards). Men with pregnant or lactating partners must be advised to use barrier method contraception (for example: condom plus spermicidal gel) to prevent exposure to the foetus or neonate.
* Any major surgical procedure within 4 weeks prior to patients scheduled Cycle 1 Day 1, any major thoracic or abdominal surgery from which the patient has not yet recovered.
* A serious or non-healing active wound, ulcer, or bone fracture.
* At high medical risk because of non-malignant systemic disease including active uncontrolled infection.
* Known to be serologically positive for Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV) or who have an active, ongoing infection or an active, known or suspected autoimmune disease or on systemic steroids.
* Concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association \[NYHA\]), prior history of cardiac ischemia or prior history of cardiac arrhythmia.
* Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this Phase I study of CA9hu-1. Participation in an observational trial or interventional clinical trial which does not involve administration of an IMP and which would not place an unacceptable burden on the patient in the opinion of the Investigator and Medical Advisor would be acceptable.
* Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.",,,INTERVENTIONAL
NCT03031522,EGFR Molecular Classification In Vivo,Molecular Imaging,COMPLETED,"Inclusion Criteria:

* Advanced NSCLC
* 18 years or older
* A life expectancy of at least 12 weeks
* Presence of a malignant lesion within the chest of at least 0.5 cm diameter as measured by computed tomography (CT)
* Written informed consent

Exclusion Criteria:

* Claustrophobia
* Pregnancy
* Metal implants in the thorax",,,INTERVENTIONAL
NCT00762034,"A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer",Non-small Cell Lung Cancer,COMPLETED,"Inclusion Criteria:

* You must sign an informed consent document for clinical research.
* You must have Stage IIIB or Stage IV nonsquamous non-small cell lung cancer.
* You must not have received any prior treatment for your disease.
* Prior radiation therapy is allowed to \< 25% of the bone marrow; however, prior radiation to the whole pelvis is not allowed. If you have had radiation therapy to the chest, you are not eligible to participate.
* You must be at least 18 years of age or older.
* You must have measureable tumor lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) or disease can be evaluated on computed tomography (CT) scan.
* Your test results assessing the function of blood forming tissue, kidneys and liver must be satisfactory.
* Women must be sterile, postmenopausal or on contraception and men must be sterile (for example post-vasectomy) or on contraception.

Exclusion Criteria:

* You cannot have clinically significant third-space fluid collections (e.g. ascites or pleural effusions that cannot be controlled by drainage or other procedures).
* You cannot have Non-small Cell Lung Carcinoma (NSCLC) of predominantly squamous cell histology.
* You cannot have known central nervous system (CNS) disease, other than stable, treated brain metastasis.
* You cannot have undergone a surgical procedure, open biopsy, open pleurodesis, or significant traumatic injury within 28 days of starting the study treatment, or have an anticipated need for major surgery during the study.
* You cannot have a history of gastrointestinal fistula, perforation, or abscess, inflammatory bowel disease, or diverticulitis.
* You are currently receiving ongoing treatment with full-dose warfarin or equivalent.
* You cannot have significant vascular disease, serious cardiac conditions (such as heart attack), stroke or transient ischemic attack within 6 months of the trial.
* You cannot have evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).
* You cannot have inadequately controlled hypertension, or a history of hypertensive crisis or hypertensive encephalopathy.
* You cannot have a serious, nonhealing wound, active ulcer, or untreated bone fracture.
* You cannot have another form of cancer, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within the last 5 years.
* You cannot have received an investigational treatment within 30 days prior to the trial.
* You cannot have previously received treatment with paclitaxel, carboplatin, pemetrexed, or bevacizumab.
* You cannot be pregnant or breast-feeding.
* You cannot have a known sensitivity to any component of paclitaxel, carboplatin, pemetrexed, or bevacizumab.
* You cannot have a history of hemoptysis (coughing blood) within 3 months prior to the trial.
* You are unable to stop taking aspirin more than 1.3 grams per day or other nonsteroidal anti-inflammatory drugs (NSAIDs).
* You are unable or unwilling to take folic acid or vitamin B12 supplementation.
* You are unable to take corticosteroids.
* You have any other on-going illnesses including active infections that may not allow you to adhere to the requirements of the trial.",,,INTERVENTIONAL
NCT04685135,Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation,"Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer",ACTIVE_NOT_RECRUITING,"Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.
* Candidacy to receive treatment with docetaxel.

Crossover Inclusion Criteria:

* Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR
* ECOG performance status 0-2

Exclusion Criteria:

* Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).
* Active brain metastases.

Crossover Exclusion Criteria:

* Receipt of any other systemic anti-cancer therapy after last administration of docetaxel on the study.",,,INTERVENTIONAL
NCT05071703,"Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study",Extensive-stage Small-cell Lung Cancer,COMPLETED,"Inclusion Criteria:

1. Voluntarily participate and sign informed consent;
2. must be at least 18 years when fisrt dose of Trilaciclib, regardless of gender:
3. Patients with extensive small-cell lung cancer confirmed by histology or cytology
4. Patients suitable for Trilaciclib combined with platinum/etoposide or Trilaciclib combined with topotecan treatment

Exclusion Criteria:

1. Patient is currently participating in other Interventional clinical studies;
2. Patients received systemic chemotherapy other than the regimens recommended in inclusion criteria 4 During Trilaciclib treatment.",,,INTERVENTIONAL
NCT03520842,Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer,"KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7",COMPLETED,"Inclusion Criteria:

* Histologic or cytologic confirmed diagnosis of non-squamous non-small cell lung cancer that is recurrent or metastatic.
* Documentation of pathogenic KRAS mutation
* Previous receipt of at least one systemic therapy for recurrent or metastatic disease OR previous receipt of adjuvant systemic therapy within 6 months of enrollment; there is no limit on number of prior therapies allowed
* Prior systemic therapy must be completed within 2 weeks of study treatment, with either improvement of clinically significant treatment-related toxicities to grade 0-1 OR stabilized to a new baseline
* Previously treated OR asymptomatic non-progressing \< 1 cm untreated brain metastases are allowed
* Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
* Ability to understand and the willingness to sign a written informed consent document
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Absolute neutrophil count (ANC) ≥ 1500/mm\^3
* Platelet count ≥ 100,000 /mm\^3
* Hemoglobin (Hb) ≥ 9 g/dL
* Serum creatinine ≤ 1.5x upper limit of normal (ULN) OR calculated (Cockcroft Gault formula) or measured creatinine clearance ≥ 50 mL/min for patients with creatinine levels \> 1.5x ULN
* Total bilirubin ≤ 1.5x ULN OR direct bilirubin ≤ ULN for patients with total bilirubin levels \> 1.5x ULN
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x ULN (≤ 5x ULN for patients with liver involvement of their cancer)
* Must be able to swallow and retain oral medication
* Women patients of childbearing potential and men patients with women partners of childbearing potential must agree to use adequate contraception or agree to abstain from heterosexual activity beginning at the time of signing informed consent until at least 3 months after the last dose of study treatment; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not considered childbearing

Exclusion Criteria:

* Previously treated with regorafenib
* Known allergy to regorafenib or methotrexate
* Currently receiving another systemic standard or investigational anti-cancer therapy; prior investigational therapy must be completed within 4 half-lives (if known) or 2 weeks, whichever is longer; the maximal washout of investigational therapy will not exceed 4 weeks prior to study treatment; bone medications such as bisphosphonates and receptor activator of nuclear factor kappa-Β (RANK) ligand inhibitors permitted
* Leptomeningeal disease as documented by cerebrospinal fluid (CSF) cytology
* Clinically significant cardiovascular related disease including:

  * Uncontrolled hypertension (systolic pressure \> 140 mm Hg or diastolic pressure \> 90 mmHg on repeated measurements, i.e., 3 or more separate days within one week) despite optimal medical management
  * Congestive heart failure - New York Heart Association (NYHA) class III or greater
  * Active coronary artery disease (i.e., unstable or new onset angina within 3 months of study treatment; myocardial infarction within 6 months of study treatment)
  * Clinically significant cardiac arrhythmias other than atrial flutter/fibrillation
  * Stroke, including transient ischemic attacks, within 6 months of study treatment
  * Other clinically significant arterial events, except for controlled asymptomatic pulmonary embolism, within 6 months of study treatment
* Clinically significant hemorrhage or bleeding event within 1 month of study treatment
* Uncontrolled symptomatic pleural effusion or ascites
* Known active additional malignancy that is undergoing or expected to undergo systemic treatment during duration of study participation
* Known history of human immunodeficiency virus (HIV) infection or known current active hepatitis B (i.e., hepatitis \[Hep\] B deoxyribonucleic acid \[DNA\] positive in prior 3 months) or hepatitis C infection (i.e., Hep C ribonucleic acid \[RNA\] positive in prior 3 months)
* Major surgical procedure (e.g., involving the opening of a major body cavity) within 4 weeks of study treatment; this does not apply to low risk procedures (i.e., thoracentesis; paracentesis; chest tube / PleurX catheter placement; line placement; needle biopsy of tumor; and bronchoscopy)
* Presence of a clinically significant non-healing wound, non-healing ulcer, or bone fracture
* Concomitant therapy required at time of first dose of study treatment, including:

  * Strong CYP3A4 inhibitors and CYP3A4 inducers
  * Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors, and probenecid
* Women who are pregnant or breast feeding
* Any condition which, in the investigator's opinion, including substance abuse, medical, psychological or social conditions that makes the patient unsuitable for trial participation or may interfere with the patient's participation in the study",,,INTERVENTIONAL
NCT03693547,Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）,Advanced Non-small Cell Lung Cancer,COMPLETED,"Inclusion Criteria:

1. Histologically or cytologically confirmed non-small cell lung cancer
2. NSCLC patients who are not suitable for surgery or radical radiotherapy or chemotherapy, or who have failed to or are intolerable for standard treatment in local advanced or metastatic NSCLC;
3. NSCLC patients failed or intolerable to previous standard second-line treatment (including platinum chemotherapy or targeted therapy);
4. Patients who did not receive chemotherapy, radiotherapy, surgical therapy, molecularly targeted drug therapy, or immunotherapy 4 weeks prior to enrollment;
5. Age 18 -70 years old, ECOG performance status of 0-1; Life expectancy of 3 months or more;
6. Patients must have measurable disease, defined as at least one target lesion that can be accurately measured by imaging techniques in at least one dimension as ≥20 mm with conventional computed tomography (CT), ≥10 mm with spiral CT scan (≥15mm for lymph node) within 3 weeks before enrolment;
7. Patients with no brain metastases or with brain metastases but are stable for more than 4 weeks after treatment;
8. Peripheral neuropathy (PN) \<grade 2 on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 within 4 weeks before enrolment;
9. Patients must have normal haematology as defined below: HGB ≥9 g/L, absolute neutrophil count ≥1.5×109/L, platelets ≥80×109/L, bilirubin ≤1.5× the upper limit of normal (ULN) (patients with liver metastasis ≤3xULN), aspartate transaminase (AST)/ alanine transaminase (ALT) ≤2.5 ×ULN (patients with liver metastasis ≤5xULN), and creatinine clearance ≥45 mL/min;
10. Patients with no major organ dysfunctions and heart disease;
11. Patients who give written informed consent with good compliance.

Exclusion Criteria:

1. Patients who are pregnant or breast feeding;
2. Patients with active tuberculosis
3. Patients with high possibility of interstitial lung disease ;
4. Patients with comorbidities, such as carcinomatous meningitis, central nervous system (CNS) metastasis, other active malignancies requiring simultaneous treatment, but not including cervical cancer in situ or basal cell carcinoma of the skin, severe disorders of the heart, lung, liver, or kidneys, severe hypertension, uncontrolled diabetes, severe gastrointestinal ulceration, active infections in need of antibiotics, or with incontrollable psychiatric history;
5. patients with HIV, untreated active hepatitis；
6. Patients with poor compliance;
7. Patients not fitted for this study determined by the investigators.",,,INTERVENTIONAL
NCT00717002,Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study,Non Small Cell Lung Cancer,COMPLETED,Patients with non small cell lung cancer.,,,OBSERVATIONAL
NCT00003881,Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer,Lung Cancer,COMPLETED,"DISEASE CHARACTERISTICS: Histologically confirmed non-small cell lung cancer (NSCLC) Recurrent AND/OR Stage IIIB with pleural or pericardial effusion OR Stage IV Must have at least one bidimensionally measurable lesion Must be HER2 positive (1-3+) Brain metastases allowed, if symptoms controlled and not requiring steroids Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: No prior chemotherapy for NSCLC Endocrine therapy: No concurrent steroids Radiotherapy: At least 2 weeks since prior radiotherapy Surgery: Not specified

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Transaminases no greater than 5 times upper limit of normal Renal: Creatinine no greater than 2 mg/dL Cardiovascular: No uncontrolled angina pectoris and arrhythmias No myocardial infarction within past 3 months No uncompensated congestive heart failure Ejection fraction at least 45% Other: No active infections Not pregnant or nursing Fertile patients must use effective contraception HIV negative No other active malignancies No evidence of peripheral sensory neuropathy of at least grade 2",,,INTERVENTIONAL
NCT04647838,Tepotinib in Solid Tumors Harboring MET Alterations,"Solid Tumor, MET Exon 14 Skipping Mutation, MET Amplification",UNKNOWN,"Inclusion Criteria:

1. Histologically or cytologically confirmed solid cancers (NSCLC, gastric cancer, colorectal cancer, breast cancer, hepatocellular cancer, head and neck cancer, RCC and other solid cancers)
2. Subjects who are not eligible for surgical and/or local-regional therapies or who have progressive disease (PD) after surgical and/or local-regional therapies
3. Subjects who have disease progression or are intolerant to the prior standard treatment for advanced solid cancers
4. A tumor biopsy (excluding fine needle aspiration and cytology samples) is required for determining MET status (a fresh pretreatment tumor biopsy is recommended but archived tumor sample is acceptable).
5. Patients with MET exon 14 skipping mutation detected by NGS method and c-MET copy number gain (≥6.0) in the archival or fresh tumor tissue specimen identified in K-MASTER panel. All genetic findings must be reviewed by the study Molecular Steering Committee, prior to study entry.
6. Male or female, 19 years of age or older
7. Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST v 1.1). The target lesion that has received previous local therapy should not be considered as measurable unless clear progression has been documented since the therapy.
8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
9. Signed and dated informed consent indicating that the subject has been informed of all the pertinent aspects of the trial prior to enrollment
10. Life expectancy judged by the Investigator of at least 3 months

Exclusion Criteria:

1\. Eligibility criteria:

1. Histologically or cytologically confirmed solid cancers (NSCLC, gastric cancer, colorectal cancer, breast cancer, hepatocellular cancer, head and neck cancer, RCC and other solid cancers)
2. Subjects who are not eligible for surgical and/or local-regional therapies or who have progressive disease (PD) after surgical and/or local-regional therapies
3. Subjects who have disease progression or are intolerant to the prior standard treatment for advanced solid cancers
4. A tumor biopsy (excluding fine needle aspiration and cytology samples) is required for determining MET status (a fresh pretreatment tumor biopsy is recommended but archived tumor sample is acceptable).
5. Patients with MET exon 14 skipping mutation detected by NGS method and c-MET copy number gain (≥6.0) in the archival or fresh tumor tissue specimen identified in K-MASTER panel. All genetic findings must be reviewed by the study Molecular Steering Committee, prior to study entry.
6. Male or female, 19 years of age or older
7. Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST v 1.1). The target lesion that has received previous local therapy should not be considered as measurable unless clear progression has been documented since the therapy.
8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
9. Signed and dated informed consent indicating that the subject has been informed of all the pertinent aspects of the trial prior to enrollment
10. Life expectancy judged by the Investigator of at least 3 months

2\. Exclusion criteria

1. Prior treatment with any agent targeting the HGF/c-MET pathway
2. Prior EGFR therapy for EGFR activating mutant NSCLC
3. Patients who received local treatment within 4 weeks prior to the first administration of tepotinib (e.g., major surgery, radiation therapy, hepatic arterial embolization, transcatheter arterial chemoembolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation). NOTE: palliative radiotherapy should be completed at least 7 days prior to the first administration of the tepotinib.
4. Prior history of organ transplant
5. Laboratory index at screening(refer to protocol)
6. Past or current history of neoplasm other than current cancer, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, node-negative thyroid cancer or other cancer curatively treated and with no evidence of disease for at least 3 years
7. Known central nervous system (CNS) or brain metastasis that is either symptomatic or untreated
8. Medical history of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested products
9. Clinically significant gastrointestinal bleeding within 4 weeks prior to the first administration of tepotinib.
10. Impaired cardiac function(refer to protocol)
11. Hypertension uncontrolled by standard therapies (not stabilized to ≤ 150/90 mmHg)
12. Subject with a family history of long QT syndrome or who take any agent that is known to prolong QT/QTc interval or with a marked prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \> 450 msec)
13. Known human immunodeficiency virus (HIV) infection
14. Subjects who were diagnosed with acute pancreatitis and/or chronic pancreatitis by related symptoms or imaging study.
15. Known or suspected drug hypersensitivity to any ingredients of tepotinib
16. Female subjects who are pregnant or lactating, or males and females of reproductive potential not willing or not able to employ a highly effective method of birth control/contraception to prevent pregnancy from 2 weeks before receiving study drug until 3 months after receiving the last dose of study drug. A highly effective method of contraception is defined as having a low failure rate (\< 1% per year) when used consistently and correctly.
17. Concurrent treatment with anti-cancer therapy
18. Substance abuse, other acute or chronic medical or psychiatric condition that may increase the risk associated with trial participation in the opinion of the Investigator
19. Participation in another interventional clinical trial within 28 days prior to the first administration of tepotinib or within a time period that is less than the cycle length for the investigational treatment (whichever is shorter), or if the subject has any AE caused by the investigational treatment that has not recovered to Grade 0-1
20. Previous anticancer treatment-related toxicities not recovered to baseline or Grade 1 (except alopecia) prior to administratin of tepotinib
21. Subjects with any concurrent medical condition or disease that will potentially compromise the conduct of the study at the discretion of the Investigators
22. Clinically significant third space fluid accumulation (despite the use of diuretics), e.g., uncontrolled pleural effusion or ascites
23. Uncontrolled venous or arterial thromboembolism",,,INTERVENTIONAL
NCT04384497,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,COVID-19,COMPLETED,"Inclusion Criteria:

* Age 18 or older
* Admitted to a study hospital
* Active COVID-19 defined as symptoms + SARS CoV-2 identified from upper or lower airway samples
* Negative pregnancy test taken before inclusion and use of an acceptable effective method of contraception until treatment discontinuation if the participant is a woman of childbearing potential
* Written informed consent after meeting with a study physician and ability and willingness to complete follow up

Exclusion Criteria:

* No matching plasma donor (Exact matching in both the ABO system is required)
* Unavailability of plasma
* Significant growth of alternative lower airway pathogen such as Streptococcus pneumoniae or Haemophilus influenzae in sputum
* Estimated glomerular filtration rate \<60 (kidney failure stage III or more)
* Pregnancy (urinary-hcg)
* Breast feeding
* History of severe allergic reactions to foods or other substances that the donor may have been exposed to (for example severe peanut allergy)
* Inability to give informed consent",,,INTERVENTIONAL
NCT06504927,Biomarker Discovery in Lung Cancer - Malaysia,Lung Cancer,RECRUITING,"Inclusion Criteria:

* Male or female subjects aged 30 and above.
* No previous history of any cancers.
* Able to provide X-ray and/or LDCT results.
* Have either COPD or pulmonary nodules measuring less than 11mm, or deemed not for biopsy by attending physician
* Willing to go back for a follow-up X-ray or LDCT scan in the next clinical follow up as per standard of care.
* Willing to provide up to 30mL of blood in month-0 (first visit) and up to 21mL in the next standard of care follow up visit (second visit).

Exclusion Criteria:

* Subject has received chemotherapy or radiotherapy for cancer treatment, and any other cancer-related treatment.
* Subject is pregnant or lactating (self-declaration).
* Subject is unwilling or unable to provide signed informed consent",,,OBSERVATIONAL
NCT02577627,"Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC","Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Colon Cancer",UNKNOWN,"Inclusion Criteria:

Lung Cancer (NSCLC):

1. Gender: Female, Male.
2. Age: Eighteen years and older at the start of treatment.
3. Stage: Pathologically or cytologically determined advanced or locally advanced NSCLC at Stage III/IV, adenocarcinoma, OR Pathologically or cytologically determined advanced or locally advanced NSCLC at Stage III/IV, NOS.
4. Lung cancer with measurable disease at the start of treatment.
5. No prior chemotherapy unless used in adjuvant therapy, completed more than 12 month before.
6. Patient has at least one quantitative measurements of at least one lesion in lung (primary tumor or metastasis) before treatment.
7. Patient has at least one quantitative measurements of at least one lesion in lung (primary tumor or metastasis) during or after the treatment.
8. Patient has at least one recorded visit to the treating oncologist before treatment.
9. Patient has at least one recorded visit to the treating oncologist during or after the treatment.
10. Treatment as per SOC for NSCLC.

Lung Cancer (SCLC):

1. Genders Eligible for Study: Female/Male patient.
2. Ages between 18 and older at the start of treatment.
3. Pathologically or cytologically determined advanced or locally advanced SCLC at Stage III/IV.
4. Lung cancer with measurable disease at the start of treatment.
5. No prior chemotherapy unless used in adjuvant therapy, completed more than 12 month ago.
6. Patient has at least one quantitative measurements of at least one lesion in lung (primary tumor or metastasis) before treatment.
7. Patient has at least one quantitative measurements of at least one lesion (primary tumor or metastasis) during or after the treatment.
8. Patient has at least one recorded visit to the treating oncologist before treatment.
9. Patient has at least one recorded visit to the treating oncologist during or after the treatment.
10. Treatment as per SOC for SCLC.

Colon Cancer:

1. Genders Eligible for Study: Female/Male patient.
2. Ages between 18 and older at the start of treatment.
3. Pathologically or cytologically determined advanced or locally advanced Colon Cancer at Stage III/IV
4. Colon cancer with measurable disease at the start of treatment
5. No prior chemotherapy unless used in adjuvant therapy, completed more than 12 month ago,
6. Patient has at least one quantitative measurements of at least one lesion (primary tumor or metastasis) before treatment
7. Patient has at least one quantitative measurements of at least one lesion (primary tumor or metastasis) during or after the treatment.
8. Patient has at least one recorded visit to the treating oncologist before treatment
9. Patient has at least one recorded visit to the treating oncologist during or after the treatment.
10. Treatment as per SOC for Colon cancer

Breast Cancer:

1. Genders Eligible for Study: Female patient.
2. Ages between 18 and older at the start of treatment.
3. Patients must have histologically confirmed breast malignancy that is either:

   * Stage III breast cancer, including inflammatory breast cancer, or
   * Stage IV breast cancer in a complete remission (bone only not allowed unless the bone scan is normal).
4. Breast cancer with measurable disease at the start of treatment.
5. No prior chemotherapy unless used in adjuvant therapy, completed more than 12 month ago.
6. Patient has at least one quantitative measurements of at least one lesion (primary tumor or metastasis) before treatment.
7. Patient has at least one quantitative measurements of at least one lesion (primary tumor or metastasis) during or after treatment.
8. Patient has at least one recorded visit to the treating oncologist before treatment.
9. Patient has at least one recorded visit to the treating oncologist during or after the treatment.
10. Treatment as per SOC for Breast cancer.

Prostate Cancer:

1. Genders Eligible for Study: Male patient.
2. Ages between 18 and older at the start of treatment.
3. Histologically confirmed prostate cancer with progressive metastatic disease based on any of the following:

   1. Rise in PSA - a minimum of 3 consecutive rising levels, with an interval of ≥1 week between each determination. The last determination must have a minimal value of ≥ 2 ng/mL and be determined within two weeks prior to enrolment.
   2. Measurable Disease by transaxial imaging - patients showing new or progressive soft tissue masses on CT or MRI scans as defined by the PCWG2.
   3. Radionuclide bone scan - at least two new metastatic lesions by CT, MRI or by any SOC.
4. Ongoing androgen depletion therapy with a Gonadotropin Releasing Hormone (GnRH) analogue or inhibitor, or orchiectomy (i.e., surgical or medical castration).
5. Patients must have castrate levels of testosterone (\<50 ng/dl \[1.74 nmol/l\]).
6. Patient has at least one recorded visit to the treating oncologist before treatment.
7. Patient has at least one recorded visit to the treating oncologist during or after the treatment.
8. Treatment as per SOC for Prostate cancer.

Exclusion Criteria:

Lung Cancer (NSCLC):

1\. History of another malignancy within the previous 2 years except for the following:

1. Adequately treated basal cell or squamous cell skin cancer,
2. Adequately treated Stage I or II cancer currently in complete remission, or any other cancer that has been in complete remission for at least 2 years.

Lung Cancer (SCLC):

1. History of another malignancy within the previous 2 years except for the following: Adequately treated basal cell or squamous cell skin cancer,
2. Adequately treated Stage I or II cancer currently in complete remission, or any other cancer that has been in complete remission for at least 2 years.

Colon Cancer:

1\. History of another malignancy within the previous 2 years except for the following:

1. Adequately treated basal cell or squamous cell skin cancer,
2. Adequately treated Stage I or II cancer currently in complete remission, or any other cancer that has been in complete remission for at least 2 years.

Breast Cancer:

1. Patients who have had chemotherapy or radiotherapy within 6 weeks prior to entering the study.
2. History of another malignancy within the previous 2 years except for the following:

   1. Adequately treated basal cell or squamous cell skin cancer,
   2. Adequately treated Stage I or II cancer currently in complete remission, or any other cancer that has been in complete remission for at least 2 years.

Prostate Cancer:

1. History of, or current known metastases in the brain or untreated spinal cord compression;
2. History of another malignancy within the previous 2 years except for the following:

   1. Adequately treated basal cell or squamous cell skin cancer,
   2. Adequately treated Stage I or II cancer currently in complete remission, or any other cancer that has been in complete remission for at least 2 years.
3. Patients have received prior cytotoxic chemotherapy for Prostate cancer.",,,OBSERVATIONAL
NCT03143322,Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases,"Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Prostate Cancer, Bone Metastases",ACTIVE_NOT_RECRUITING,"Inclusion Criteria:

1. Patients older than 18 years and younger than 75 years
2. Good general condition: WHO performance status ≤ 2
3. Patients with histological proof of breast, non-small cell lung, or prostate cancer Note: Histological proof can be done on the primitive tumour and/or adenopathy and/or metastatic site.
4. Absence of co-morbidity contra-indicating radio-chemotherapy or surgery
5. Primary tumor accessible to curative-intent treatment (surgery, chemoradiation…) for patients with synchronous metastases
6. Patients with between 1 and 5 synchronous or metachronous bone metastases as defined by NaF-PET or conventional SPECT-CT scan and spinal MRI (if necessary) within 6 weeks before randomization)
7. Bones metastases treatable by SBRT
8. Primary cancer considered to be controlled or accessible to curative-intent treatment (surgery, chemoradiation…) in case of locoregional recurrence for metachronous bone oligo-metastatic disease
9. Women of childbearing potential and male patients must agree to use adequate contraception for the duration of study participation and up to 3 months following completion of therapy
10. Patients who have received the information sheet, dated and signed the informed consent form
11. Affiliated to the social security system

Exclusion Criteria:

1. Visceral metastases as defined by FDG-PET (F-Choline-PET or PSMA PET-CT for prostate cancer) and cerebral CT or MRI performed.
2. Previous systemic therapy for metastasis for patients with metachronous metastasis. Prostate and breast cancer patients remain eligible if hormonal treatment was initiated 6 months before enrollment
3. All bone metastasis requiring surgical treatment (spinal cord compression, fracture…)
4. More than 5 bone metastases as defined by NaF-PET or conventional SPECT-CT scan and spinal MRI (if spinal bone metastases on NaF-PET)
5. Previous cancer within the 5 years before inclusion (except basal cell carcinoma of the skin, in situ carcinoma of the uterine cervix)
6. Previous radiotherapy on bone metastasis (e.g: antalgic radiotherapy)
7. Patient enrolled in another therapeutic trial
8. Pregnant women or breast feeding mothers,
9. Hypersensitivity to the active substance (FDG and NaF or F-Choline or PSMA for prostate cancer) or to any of the excipients
10. Contraindication to MRI (in case of spinal metastases)
11. Patients deprived of liberty or placed under the authority of a tutor. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. Patients unable to understand the purpose of the study (language, etc.).",,,INTERVENTIONAL
NCT05462717,Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors,"Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor",ACTIVE_NOT_RECRUITING,"Inclusion Criteria:

* Subject must be ≥18 years of age.
* Subject must have pathologically documented, locally advanced or metastatic KRASG12C-mutated solid tumor malignancy (not amenable to curative surgery) that has previously been treated with standard-of-care therapies for respective tumor types, is intolerant to, or is considered ineligible for standard-of-care anticancer treatments.
* ECOG performance status 0 or 1
* Prior treatment with a KRASG12C (OFF) inhibitor allowed for dose escalation
* Adequate organ function

Exclusion Criteria:

* Primary central nervous system (CNS) tumors
* Active brain metastases
* Known impairment of GI function that would alter the absorption
* Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment.
* Prior therapy with KRASG12C (ON) inhibitor

Other inclusion/exclusion criteria may apply.",,,INTERVENTIONAL
NCT06221462,Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer,"Carcinoma, Non-Small-Cell Lung",NOT_YET_RECRUITING,"Inclusion Criteria:

1. Providing written informed consent prior to initiating the study.
2. Regardless of sex, aged ≥18 years and ≤75 years.
3. Histologically confirmed NSCLC.
4. At least one radiologically measureable lesion according to response evaluation criteria in solid tumors version 1.1(RECIST V1.1).
5. Treatment-naïve IB-IIIB resectable NSCLC (American Joint Committee on Cancer 8th tumor-node-metastasis classification).
6. Epidermal growth factor receptor(EFGR)/anaplastic lymphoma kinase(ALK)/ROS proto-oncogene 1(ROS1) wild type NSCLC.
7. Absence of bleeding risk.
8. Consent to surgical treatment.
9. Indication for surgery confirmed by surgeons.
10. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
11. Expected survival time more than 6 months.
12. Sufficient organ reserve, detailed as follows:(1) the absolute neutrophil count ≥1.5×109/L without the use of granulocyte colony-stimulating factor for the past 14 days prior to the first dose of study drugs;(2) platelet count ≥100×109/L without blood transfusion within the 2 weeks before the enrollment;(3) hemoglobin \>9g/dL without recent usage of blood transfusion 14 days prior to the study;(4) total bilirubin ≤ 1.5 fold the upper limit of normal (ULN), or total bilirubin \>1.5 fold ULN but direct bilirubin ≤ 1 fold ULN;(5) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN;(6) blood creatinine ≤ 1.5 fold ULN and creatinine clearance (calculated by the Cockcroft-Gault formula) ≥ 60ml/min;(7) adequate coagulation function, defined by international normalized ratio (INR) or prothrombin time(PT) less than 1.5 fold ULN;(8) normal thyroid function defined by the normal range of thyroid-stimulating hormone (TSH); otherwise, abnormal level of TSH with normal range of T3(or Ft3) and Ft4;(8) cardiac enzyme profile within the normal limits (merely laboratory abnormity without clinical significance based on investigator's decision is allowed)
13. For female participants of childbearing age, a urine or serum pregnancy test should be performed within 3 days before receiving the first dose of the study drugs, and the result must be negative. If the urine pregnancy test result is inconclusive, a blood pregnancy test is warranted. Postmenopausal women are defined as those who have been without menstruation for at least 1 year, or have undergone surgical sterilization or hysterectomy.
14. In the presence of pregnancy risk, all participants (both male and female) are required to use contraceptive measures with an annual failure rate of less than 1% throughout the entire treatment period up to 120 days following the last dose of the study drugs.

Exclusion Criteria:

Exclusion criteria as follows：

1. Other malignancy rather than NSCLC diagnosed within 5 years prior to the first dose of the study given, except for definitively treated basal cell carcinoma, squamous cell carcinoma of the skin, and/or in situ carcinoma.
2. Enrolled in an ongoing interventional clinical trial, or receiving other study drugs or study medical devices within 4 weeks prior to the first dose of this study drugs.
3. A history of receiving the following therapies: anti-programmed cell death-1 (anti-PD-1), anti-programmed cell death ligand-1 (anti-PD-L1) or anti-programmed cell death ligand-2 (anti-PD-L2) drugs, or drugs targeting T cell receptor (such as cytotoxic T-lymphocyte-associated protein 4, tumor necrosis factor receptor superfamily member 4 and CD137).
4. A history of receiving targeted therapy such as anti-vascular endothelial growth receptor (VEGR)/ vascular endothelial growth factor receptor (VEGFR), rapidly accelerated fibrosarcoma(RAF), mitogen-activated protein kinase(MAPK), platelet-derived growth factor Receptor(PDGFR) or fibroblast growth factor receptor(FGFR).
5. Receiving traditional Chinese medication or immunomodulatory drugs (including thymopentin, interferon, interleukin, except for controlling pleural effusion) as systemic therapy within 2 weeks prior to the first dose of the study drugs.
6. Active systemic auto-immune disease requiring systemic treatment within 2 years prior to the first dose of the study drugs, such as the use of disease-modifying drugs, glucocorticoids or immunosuppressants. Alternative therapies (such as thyroid hormone, insulin, or physiological glucocorticoids used for adrenal or pituitary insufficiency) are not considered as systemic treatment.
7. Systemic glucocorticoid therapy (excluding nasal, inhaled or other local routes of glucocorticoids) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugs.
8. Undergoing allogeneic organ transplant (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplant.
9. Allergy to the active ingredient or excipients of the study drug, sintilimab.
10. Having not recovered from any toxicities and/or complications caused by prior interventions before the initiation of the study (i.e., ≤ Grade 1 or to baseline, excluding fatigue or hair loss)
11. Known history of human immunodeficiency virus (HIV) infection.
12. Untreated active hepatitis B (defined as hepatitis B surface antigen positive with detectable hepatitis B virus(HBV)-DNA copies exceeding the upper limit of normal values).
13. Active hepatitis C infection.
14. Receiving a live vaccine within 30 days prior to the first dose of the study drug.
15. Pregnant or lactating women.
16. Other investigator's defined uncontrolled systemic disease.",,,INTERVENTIONAL
NCT05343637,A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension,COMPLETED,"Inclusion Criteria:

1. Between 18 and 80 years of age, inclusive.
2. Diagnosis of RHC-confirmed WHO Group 1 PAH in any of the following three categories: Idiopathic, primary or familial pulmonary arterial hypertension (IPAH, PPH, or FPAH); OR PAH associated with one of the following connective tissue diseases (CTD):

   1. Systemic sclerosis (scleroderma)
   2. Limited scleroderma
   3. Mixed connective tissue disease
   4. Systemic lupus erythematosus
   5. Overlap syndrome
   6. Other autoimmune disorders;

   OR PAH associated with:
   1. Human immunodeficiency virus (HIV) infection with no evidence of opportunistic infection in the preceding 6 months;
   2. Simple, congenital systemic-to-pulmonary shunts at least one-year post-surgical repair.
   3. Exposure to legal drugs, chemicals and toxins, such as fenfluramine, derivatives, other anorexigens, toxic rapeseed oil or L-tryptophan. Subjects with PAH associated with illegal drug use, such as methamphetamine, were excluded.
3. Previous diagnosis with PAH with the following conditions:

   1. Stable PAH without significant adjustments of disease-specific background PAH therapy, at least 3 months prior to RHC procedure;
   2. If on corticosteroids, has been receiving a stable dose of ≤ 20 mg/day of prednisone (or equivalent dose of other corticosteroid) for at least 30 days prior to RHC procedure.
4. Pulmonary Function Tests within 24 months prior to RHC procedure that fulfilled the following criteria (pulmonary function; (PFT may be assessed at Screening if historical PFT results are not available):

   1. Forced Expiratory volume in one second (FEV1) ≥ 60% predicted (pre-bronchodilators);
   2. FEV1/ forced expiratory vital capacity (FVC) ≥ 60% (pre-bronchodilators);
   3. FVC ≥ 60% predicted.

Exclusion Criteria:

1. Baseline systemic hypotension, defined as MAP \< 50 mmHg or systolic blood pressure (SBP)\< 90 mmHg at Screening.
2. Requirement of intravenous inotropes within 30 days prior to RHC procedure.
3. Use of oral, topical or inhaled nitrates within 14 days prior to RHC procedure.
4. Uncontrolled systemic hypertension: SBP \> 160 mmHg or diastolic blood pressure (DBP) \>100 mmHg at Screening.
5. History of portal hypertension or chronic liver disease, including active viral replication of hepatitis B and/or hepatitis C or classified as having moderate to severe hepatic impairment (Child-Pugh Class B-C).
6. Chronic renal insufficiency as defined by serum creatinine \> 2.5 mg/dL at Screening or requires dialysis.
7. History of atrial septostomy.
8. Unrepaired congenital heart disease (CHD).
9. Pericardial constriction; restrictive or congestive cardiomyopathy.
10. History of left ventricular ejection fraction (EF) \< 40% by multiple gated acquisition scan (MUGA), angiography, echocardiography, or cardiac magnetic resonance imaging (CMRI).
11. Symptomatic coronary disease with demonstrable ischemia.
12. Poorly controlled asthma defined by active wheezing and/or cough at the time of Screening or day of participation in Parts A and B.
13. Clinically significant intercurrent illness (including lower respiratory tract infection) or clinically significant surgery within 30 days prior to study drug administration.
14. Clinical RHC \< 14 days prior to Screening.
15. History of non-arteritic anterior ischemic optic neuropathy (NAION) or retinitis pigmentosa.",,,INTERVENTIONAL
NCT00008255,INS316 in Diagnosing Lung Cancer in Patients With Untreated Lung Cancer,Lung Cancer,COMPLETED,"DISEASE CHARACTERISTICS: Histologically or cytologically proven primary lung cancer OR Presumptive diagnosis based on chest x-ray, CT scan, history, or symptoms No prior treatment

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Pulmonary: FEV1 at least 35% predicted Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other comorbid condition that would preclude study

PRIOR CONCURRENT THERAPY: See Disease Characteristics At least 4 days since prior bronchoscopic examination or pulmonary fine needle aspiration biopsy At least 3 days since prior sputum induction No concurrent medication that would preclude study At least 30 days since prior investigational drugs (including INS316) or experimental therapy",,,INTERVENTIONAL
NCT00495170,Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC),Lung Cancer,COMPLETED,"Inclusion Criteria:

1. Histologically or cytologically documented NSCLC.
2. Inoperable stage IIIA (T1--3N2MO, T3N1MO) and IIIB (T1-3N3MO, T4NO-3MO) disease excluding malignant pleural effusion.
3. Performance score Karnofsky Performance Status (KPS) 70-100, Weight loss: less or equal to 10% in 6 months prior to diagnosis.
4. Patient consented for the protocol
5. Induction chemotherapy is allowed.

Exclusion Criteria:

1. Prior chest radiotherapy.
2. Previous or concomitant malignancy other than (a) curatively treated carcinoma in situ of cervix, (b) basal cell carcinoma of the skin, (c) curatively treated superficial transitional cell carcinoma of the urinary bladder, and (d) early stage tumor treated more than 3 years ago for cure.
3. Pregnancy. Patients (men and women) of child bearing potential should use an effective (for them) method of birth control throughout their participation in this study.
4. Off study criteria: a) If a patient is found to have distant metastasis during treatment and/or immediate after the treatment (\<60 days) indicating inaccurate cancer stage, he or she will be taken off study. b) If a patient does not follow up at MD Anderson and does not forward his or her medical records such as CT, PET/CT, pulmonary function test (PFT) or pathology report as required by protocol, he or she will be taken off study. c) If a patient does not have any required post-treatment evaluation such as images, he or she will be taken off study.",,,INTERVENTIONAL
NCT04869267,Acceptance and Commitment Therapy in Patients With Advanced Lung Cancer,"Lung Cancer, Advanced Cancer",COMPLETED,"Inclusion Criteria:

1. aged 18 or over;
2. diagnosed with stage III or stage IV lung cancer by pathological section or cytology;
3. experienced unexplained fatigue syndrome: the score of 3 or more on the Fatigue Symptom Inventory (FSI); and
4. able to provide informed consent and effectively collect data.

Exclusion Criteria:

1. diagnosed with cognitive dysfunction or other mental illnesses that may interfere with their completion of treatment;
2. who are with a life expectancy \<3 months, or whose physical conditions are considered ineligible for the present study based on the physician's judgment; and
3. who are receiving or have just completed other lung cancer-related intervention programs within the last six months",,,INTERVENTIONAL
NCT03984747,Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection,"Transplant Rejection, Allograft Rejection, Complications",COMPLETED,"Inclusion Criteria:

* Subject must be 2 years old or older at the time of enrollment
* Subject or Legally Authorized Representative is willing and able to sign the informed consent form (and assent form, if applicable), prior to participation in any study-related procedures.
* Subject has received at least one organ transplant prior to enrollment.

Exclusion Criteria:

* Pediatric subjects under 2 years old
* Subject received donor organ from an identical twin",,,OBSERVATIONAL
NCT00243347,The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer,"Carcinoma, Non-Small-Cell Lung Carcinoma, Head and Neck Neoplasms",COMPLETED,"Inclusion Criteria:

* Histologically or cytologically confirmed head and neck cancer (HNC) or unresectable stage IIIb or IV non-small cell lung cancer (NSCLC)
* At least one lesion able to be used for tumor biopsy and to be measured by FDG-PET Scan
* Considered suitable for treatment of NSCLC with no prior biological or immunological therapy for disease
* Or considered suitable for treatment for metastatic or recurrent HNC with no prior biological or immunological therapy for disease

Exclusion Criteria:

* NSCLC: Have received more than 2 previous chemotherapy regimens or have received the last chemotherapy or radiotherapy within 28 days of first dose of AZD2171
* HNC: Previous chemotherapy or radiotherapy if received 28 days of first dose of AZD2171
* Untreatable, unstable brain or meningeal metastases.
* Abnormal liver and kidney blood chemistries
* History of poorly controlled hypertension with resting blood pressure of \>150/100
* Recent (\< 14 days) major surgery or a surgical incision not fully healed
* Diabetes patients with type I insulin dependent diabetes or poorly controlled type II
* Significant hemorrhage or hemoptysis
* Presence of necrotic/hemorrhagic tumor or metastases",,,INTERVENTIONAL
NCT06526819,SMP-3124LP in Adults With Advanced Solid Tumors,Solid Tumor,RECRUITING,"Inclusion Criteria:

\- Histologically or cytologically-confirmed cancer that is advanced, recurrent, or metastatic with the following origins, and whose disease progressed on standard therapy and for whom there are no alternative therapies that may confer overall survival benefit.

For patients in the Dose Escalation part:

1. Platinum-resistant ovarian cancer

   * Histologically diagnosed ovarian, fallopian tube, or primary peritoneal cancer, with predominantly high-grade (Grade 2 or 3) epithelial features (serous and clear cell)
   * Platinum resistant is defined as relapsed within 6 months after the last dose of platinum-based therapy
2. Triple negative breast cancer - ER- and PR-negative with HER2 negative

   * HER2 negative is defined as one of the following: 0 or 1+ by IHC, or if IHC 2+, then in situ hybridization is negative per the ASCO-CAP HER2 guidelines
   * ER- and PR-negative is defined as \< 10% of cells expressing hormonal receptors by IHC, as per standard guidelines
3. Squamous cell carcinoma of the anus

   \- Patient with locally advanced ineligible for surgery is allowed.
4. Squamous cell carcinoma of the head and neck
5. Non-small cell lung cancer (NSCLC: adenocarcinoma, large cell, and squamous cell carcinoma)
6. Uterine serous cancer (recurrent or persistent)

   For Patients in the Dose Expansion Part:
7. Cohort A: PROC (same as above)
8. Cohort B: TNBC (same as above)
9. Cohort C: SCCA (same as above)

   * ECOG performance \</= 2 at screening
   * Recovered from any prior treatment related toxicities
   * Adequate organ function as evidenced by:

a. Hemoglobin \>/= 9 g/dL (transfusion or use of erythropoietin to obtain this are not permitted) b. Absolute neutrophil count \>/= 1500 uL (platelet transfusion not allowed to achieve this) c. Platelet count \>/= 100 x 10 (platelet transfusion not alled to achieve this) d. Bilirubin \</= 1.5 x ULN (or \</= 3.0 x if ULN if Gilbert's syndrome) e. AST and ALT \</= 3.0 x ULN (or \</= 5 x ULN if the liver has tumor involvement f. Calculated creatinine clearance \>/= 60 mL/min using Cockcroft-Gault formula

* Patient is non-fertile or agrees to use adequate methods of contraception or agrees to refrain completely from heterosexual intercourse during the study and for 6 months (for female and male patients alike) after the last dose of study intervention.
* May be HIV positive if the following conditions are met:

  1. CD4 + T-cell count \>/= 350 cells/uL
  2. HIV viral load \< 400 copies/ml prior to enrollment
  3. No history of acquired immunodefficiency syndrome (AIDS) defining opportunistic infections
* Known hepatitis B infection mush have negative serum HbsAg. Patients with known hepatitis C virus infection must have a viral load below the limit of quantification Japan sites only: HBc antibody or HBsantibody tests should be performed if HBsAg is negative. If HBc antibody or HBs antibody tests are positive, HBV DNA quantitative tests should be performed to confirm that HBV DNA is negative.

Exclusion Criteria:

* Patient has received prior treatment at any time with a cell cycle checkpoint inhibitor (eg, CHK1 and/or CHK2, WEE1, or ATR inhibition)
* Patient has a known allergy or sensitivity to any component of SMP-3124LP, including the inactive ingredients
* Patient has received treatment with systemic anticancer therapy, radiotherapy, or investigational therapy within 14 days prior to Study Cycle 1 Day 1. (Palliative radiotherapy with a limited field of radiation within 2 weeks will be permitted.)
* Patient has undergone a major surgical procedure ≤ 28 days, or minor surgical procedure ≤ 7 days, prior to Cycle 1 Day 1
* Patient has used strong CYP1A2 or 2D6 inhibitors within 14 days or 5 half-lives, whichever occurs first, prior to Cycle 1 Day 1 (examples of restricted CYP1A2 and CYP2D6, P-gp, and/or BCRP inducers, inhibitors, or substrates are presented in Table 16)
* Patient has central nervous system metastasis or leptomeningeal disease
* Prior or concurrent malignancy whose natural history or treatment would have a significant potential to interfere with the safety or efficacy assessments of the investigational regimen
* Patient has an abnormal ECG that is clinically significant, including a corrected QT interval (corrected using Fridericia's correction formula \[QTcF\]) \> 470 msec; and/or a history of Torsade de Pointes
* Patient has a left ventricular ejection fraction \< 45% by echocardiogram (ECHO)
* Patient has clinically significant cardiac disease including heart failure (eg, New York Heart Association, Class III or IV)
* Patient has an active, uncontrolled, bacterial, viral, or fungal infection requiring parenteral antimicrobial within 1 weeks prior to Cycle 1 Day 1
* Patient is pregnant (as evidenced by a positive serum or urine pregnancy test) or is breastfeeding. Female breastfeeding patients may be enrolled if they interrupt breastfeeding. Breastfeeding should not be resumed for at least 6 months after the last dose of study drug.

For sites in Japan only: In addition to the above, any patient deemed likely to be pregnant based on medical interview will be excluded from the study.

* Patient with ovarian cancer

  1. Has a history of bowel obstruction related to their underlying disease within 3 months prior to Study Day 1
  2. Has platinum-refractory disease. Platinum refractory is defined as progression during platinum-based chemotherapy
* Patient has any other medical or psychiatric condition that, in the opinion of the investigator, might interfere with their participation in the trial or interfere with the interpretation of trial results
* Patient is taking a prohibited medication at baseline.",,,INTERVENTIONAL
NCT04383938,Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies,"Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC, Urothelial Carcinoma, Advanced Solid Tumor",COMPLETED,"Inclusion Criteria:

1. Signed informed consent form (ICF) and ability to comply with protocol requirements.
2. Known tumor TP53 mutation status from recent or archival sample.
3. Histologically and/or cytologically confirmed solid tumor malignancy

   1. Safety lead in- Advanced non-central nervous system (CNS) primary tumors that have progressed after first line treatment, who are intolerant to first line treatment, or who are unable to receive first line treatment, and for whom pembrolizumab, or pembrolizumab-based therapy is considered appropriate
   2. Expansion 1- Patients with a confirmed diagnosis of advanced gastric or gastroesophageal junction (GEJ) tumors that have progressed after first line treatment, who are intolerant to first line treatment, or who are unable to receive first line treatment
   3. Expansion 2- Patients with a confirmed diagnosis of advanced bladder/urothelial tumors that have progressed after first line treatment, or who are intolerant to first line treatment, or who are unable to receive first line treatment with cisplatin-based chemotherapy.
   4. Expansion 3- Confirmed diagnosis of advanced non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy.
4. Adequate organ function

   1. Creatinine clearance \> 30 mL/min
   2. Total serum bilirubin \< 1.5 × upper limit of normal (ULN) unless due to Gilbert's syndrome, tumor involvement, hemolysis or considered an effect of regular blood transfusions
   3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 3 × ULN, unless due to involvement by the underlying malignancy.
5. Projected life expectancy of ≥ 12 weeks.
6. Age ≥ 18 years at the time of signing the ICF.
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
8. In the expansion portion, measurable disease meeting the following criteria:

   1. At least 1 lesion of ≥10 mm in the longest diameter (LD) for a non-lymph node or ≥15 mm in the short-axis diameter for a lymph node that is serially measurable according to RECIST 1.1.
   2. Lesions that have had external beam radiotherapy or loco-regional therapies such as radiofrequency ablation must show subsequent evidence of substantial size increase (ex. 20% increase in LD) to be deemed a target lesion.
9. Negative serum or urine pregnancy test prior to study treatment initiation in female subjects of childbearing potential.
10. Women of childbearing potential and men with female partners of childbearing potential must be willing to use an effective form of contraception

Exclusion Criteria:

1. Known history of untreated human immunodeficiency virus (HIV)/HIV with a detectable viral load or active hepatitis B or active hepatitis C infection.
2. Cardiac abnormalities
3. Concomitant malignancies or previous malignancies with less than a 1-year disease-free interval at the time of signing consent.
4. Pregnancy or lactation.
5. Active uncontrolled systemic infection.
6. An autoimmune condition requiring ≥ 10 mg (or equivalent corticosteroid) prednisone daily, or any other systemic immunosuppressive treatment within 28 days of first dose of study therapy.
7. Known history of active tuberculosis.
8. Current (non-infectious) pneumonitis, or a history of pneumonitis that required steroids.
9. A live vaccine administered within 30 days of the first dose of study treatment.
10. Receipt of any investigational product within 14 days or 5 half-lives prior to study treatment initiation, whichever is shortest.
11. Prior intolerance to pembrolizumab or other anti-PD-1/PD-L1 agents.",,,INTERVENTIONAL
NCT06522750,Periodic Fasting for Treatment of Long Covid in Adults: a Pilot Study,"Long Covid, Chronic Inflammation",RECRUITING,"Inclusion Criteria:

* Age 18-64
* Diagnosis Long Covid Syndrome (post-acute COVID-19 symptoms persisting ≥12 weeks)
* Normal body Mass Index (18.5 to 25 kg/m2)
* Marginal Iron status ( PF\< 25 ng/ml)
* Able to communicate in and comprehend English and/or German and/or French language
* Present written / signed declaration of consent
* Ability to understand the patient information and willingness to sign the consent form
* Consent to specimen collection and specimen use

Exclusion Criteria:

* Current underweight condition (body mass index less than 18.5 kg/m2) or weight loss exceeding 3 kg within the last month or 5 kg within the last three months.
* Existing / current eating disorder within the past five years (e.g., anorexia, bulimia).
* Psychiatric condition that limits understanding of the examination protocol (unable to consent)
* Severe internal disease (e.g. kidney deficiency with creatinine \> 2mg/dl), chronic inflammatory illness other than LCS
* Participation in another intervention study.
* Existing vegan diet or fasting during the last six months
* Pregnancy or breastfeeding status.
* Presence or suspicion of pre-existing ME/CFS or early autonomous dysfunction
* Diagnosis of chronic inflammatory bowel diseases, celiac disease or colorectal cancer according to the guidelines of the German Society of Gastroenterology
* Use of anti-psychotic drugs
* Antibiotic use during the previous 12 months
* Start of novel drug therapy
* Contraindication for additional blood draws (e.g. hemoglobin \<10)",,,INTERVENTIONAL
NCT04665856,Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer,Small Cell Lung Carcinoma,ACTIVE_NOT_RECRUITING,"Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
* Histologically or cytologically confirmed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) per the modified Veterans Administration Lung Study Group (VALG) staging system
* No prior systemic treatment for ES-SCLC
* For participants who have received prior chemoradiotherapy for limited-stage SCLC must have had treatment with curative intent and a treatment-free interval of at least 6 months between the last dose/cycle of chemotherapy, thoracic radiotherapy, or chemoradiotherapy and the diagnosis of ES-SCLC
* Measurable diseases as defined by RECIST v1.1
* Submission of a pre-treatment tumor tissue sample
* Adequate hematologic and end-organ function
* Participants not receiving therapeutic anticoagulation with International Normalized Ratio (INR) and Activated Clotting Time (aPTT) \</= 1.5 x ULN
* Participants receiving therapeutic anticoagulation: stable anticoagulant regimen
* Negative Human Immunodeficiency Virus (HIV) test at screening
* Negative hepatitis B surface antigen (HBsAg) test at screening
* Positive hepatitis B surface antibody (HBsAb) test at screening, or negative HBsAb at screening accompanied by either of the following: negative total hepatitis B core antibody (HBcAb) and/or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test
* Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test
* Negative Epstein-Barr virus (EBV) viral capsid antigen (VCA) IgM test or negative EBV polymerase chain reaction (PCR) test at screening
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs
* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm.

Exclusion Criteria:

* Symptomatic or actively progressing central nervous system (CNS) metastases
* Spinal cord compression
* Leptomeningeal disease
* Uncontrolled pleural effusion, pericardial effusion, or ascites
* Uncontrolled or symptomatic hypercalcemia
* Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, and inherited liver disease, or current alcohol abuse
* Malignancies other than SCLC within 5 years prior to randomization
* Active or history of autoimmune disease or immune deficiencies
* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computer Tomography (CT) scan
* Known active tuberculosis, Current treatment with anti-viral therapy for HBV or HCV
* Severe chronic or active infection
* Treatment with therapeutic oral or IV antibiotics
* Significant cardiovascular disease
* Major surgical procedure other than for diagnosis
* Prior allogeneic bone marrow transplantation or solid organ transplant
* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition
* Administration of a live, attenuated vaccine
* Prior treatment with CD137 agonists, T-cell co-stimulating, or immune checkpoint blockade therapies
* Treatment with systemic immunostimulatory agents
* Treatment with systemic immunosuppressive medications
* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
* Known hypersensitivity to Chinese Hamster Ovary (CHO) cell products or to any component of the tiragolumab or atezolizumab formulations
* History of allergic reactions to carboplatin or etoposide
* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab or within 90 days after the final dose of tiragolumab or for 6 months after the final dose of carboplatin or etoposide.",,,INTERVENTIONAL
NCT00547105,Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Lung Cancer,COMPLETED,"Inclusion Criteria

Patients must meet all of the following inclusion criteria to be eligible for participation in this study:

1. Patients must have biopsy proven NSCLC that is locally advanced or metastatic.
2. Patients must have had failure of at least one prior chemotherapy regimen.
3. Patients must not have started erlotinib therapy more than 4 weeks prior to the initiation of SBRT.
4. Age ≥ 18 years
5. Patients must have measurable disease at baseline.
6. Patients can have up to only 6 discrete active extracranial lesions (≤3 in the liver and ≤3 in the lung) identified by PET scan and also seen on correlative plain film, CT scan, or MRI within 8 weeks prior to the initiation of SBRT.

   1. For patients who have received prior radiotherapy to the primary site in the lung, residual PET activity is difficult to interpret and will not be considered a site of active disease if the CT appearance is stable or improved over an interval of at least three months
   2. Patients who previously received radiotherapy to the primary site will be ineligible if there is CT evidence of disease progression within the past 3 months.
   3. Patients with previously un-irradiated primary sites will be potentially eligible, but special considerations apply (section 4.3.2).
   4. Up to 2 contiguous vertebral metastases will be considered a single site of disease.
7. Patients must have a KPS \>60
8. AST, ALT \& Alkaline phosphates must be ≤ 2.5X the upper limit of normal. Total bilirubin must be within the limit of normal.
9. Patients should have adequate bone marrow function as defined by peripheral granulocyte count of ≥1500/mm³.
10. Patients should have adequate renal function (serum creatinine ≤1.5 times the ULN).
11. Females of childbearing potential should have a negative pregnancy test.
12. Patients who would be receiving SBRT for lung tumors who are known or suspected by the treating radiation oncologist to have compromised lung function must have a documented forced expiratory volume in 1 second (FEV1) ≥ 1L.
13. Patients must provide verbal and written informed consent to participate in the study.
14. Total bilirubin: within normal institutional limits

Exclusion Criteria Patients who meet any of the following exclusion criteria are not to be enrolled in this study.

1. Patients who previously received radiotherapy to the primary site with CT evidence of disease progression at the primary site within 3 months following the initial radiotherapy.
2. Patients with either untreated brain metastases or brain metastases treated within the past three months are ineligible
3. Patients with serious, uncontrolled, concurrent infection(s).
4. Significant weight loss (\>10%) in the prior 3 months.
5. Because the tolerance dose of SBRT to the gastrointestinal tract is not established, patients with metastatic disease invading the esophagus, stomach, intestines, or mesenteric lymph nodes will not be eligible.
6. Patients with cutaneous metastasis of NSCLC.
7. Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cancers.
8. Patients with more than 6 discrete extra-cranial lesions.
9. Participation in any investigational drug study within 4 weeks preceding the start of study treatment.
10. Unwillingness to participate or inability to comply with the protocol for the duration of the study.
11. Patients who are pregnant. Patients with reproductive capability will need to use adequate contraception during the time of participation in the study.
12. Patients who have had prior EGFR inhibitors.",,,INTERVENTIONAL
NCT01540201,The Effect of Different I:E Ratio on Gas Exchange of Patients Undergoing One-lung Ventilation for Lung Surgery,"Lung Cancer, One Lung Ventilation, Gas Exchange, Inverse-ratio Ventilation",COMPLETED,"Inclusion Criteria:

* patients undergoing elective lung lobectomy surgery.
* the duration of one-lung ventilation is more than one hour.
* subjects with more than twenty years old.

Exclusion Criteria:

* subjects with past history of pneumothorax, asthma
* Age under 20, more than 70 years.
* Patients with ischemic heart disease, valvular heart disease
* patients with hemodynamic unstability",,,INTERVENTIONAL
NCT00052494,Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer,Lung Cancer,COMPLETED,"DISEASE CHARACTERISTICS:

* Histologically confirmed extensive stage small cell lung cancer

  * Incurable but amenable to treatment with chemotherapy
  * c-kit positive by immunohistochemistry of original biopsy or other metastatic site
* At least one unidimensionally measurable lesion

  * \> 20 mm by conventional techniques or \> 10 mm by spiral CT scan
  * No prior radiotherapy to target measurable lesion(s), unless there is documented disease progression
* No known brain metastases

PATIENT CHARACTERISTICS:

Age

* Not specified

Performance status

* ECOG 0-1 OR
* Karnofsky 70-100%

Life expectancy

* More than 6 weeks

Hematopoietic

* WBC ≥ 3,000/mm\^3
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3

Hepatic

* Bilirubin normal
* AST and/or ALT ≤ 2.5 times upper limit of normal

Renal

* Creatinine normal OR
* Creatinine clearance ≥ 60 mL/min

Cardiovascular

* No symptomatic congestive heart failure
* No unstable angina pectoris
* No cardiac arrhythmia

Gastrointestinal

* No concurrent untreated upper gastrointestinal bleeding that has not been fully investigated
* No gastrointestinal disease that would impair drug absorption

Other

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective barrier contraception prior to, during, and for 3 months after study participation
* No history of ototoxicity
* No history of peripheral neuropathy
* No traumatic injury within the past 21 days
* No ongoing or active infection
* No other concurrent significant medical condition that would preclude study participation
* No concurrent psychiatric condition or social situation that would preclude study compliance
* No other malignancy within the past 5 years except treated nonmelanoma skin cancer, carcinoma in situ, or stage A prostate cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy

* Not specified

Chemotherapy

* See Disease Characteristics
* No prior chemotherapy
* No other concurrent chemotherapy

Endocrine therapy

* Not specified

Radiotherapy

* See Disease Characteristics
* More than 4 weeks since prior radiotherapy
* No prior radiotherapy to more than 25% of marrow

Surgery

* More than 3 weeks since prior major surgery
* No prior surgical procedure impairing absorption

Other

* No prior c-kit-targeted therapy
* No concurrent therapeutic dose of warfarin

  * Mini-dose warfarin for prophylaxis and low-molecular weight heparin allowed
* No concurrent combination antiretroviral therapy for HIV-positive patients
* No other concurrent investigational agents
* No concurrent amifostine
* No other concurrent anticancer therapy",,,INTERVENTIONAL
NCT04541706,Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India,Advanced Non-Small Cell Lung Cancer,COMPLETED,"Inclusion Criteria:

1. Evidence of histologically or cytologically confirmed diagnosis of unresectable advanced and/or recurrent NSCLC that carries an ALK rearrangement, as detected by an appropriate test.
2. Disease progression or intolerance to 1 previous treatment with ALK TKI. Participants may have also had prior chemotherapy for their advanced and/or recurrent disease.
3. Participants with asymptomatic CNS metastases (including participants controlled with stable or decreasing steroid use within the last 2 weeks prior to study enrollment) will be eligible.
4. Age ≥18 years.
5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2.
6. Adequate hematologic and renal function as defined as:

   1. Absolute neutrophil count (ANC) ≥1,000/mm3;
   2. Platelets ≥50,000/mm3;
   3. Hemoglobin ≥8 g/dL;
   4. Estimated creatinine clearance ≥30 mL/min as calculated using the method standard for the institution.
7. Adequate liver function, including:

   1. Total serum bilirubin ≤1.5 × upper limit of normal (ULN);
   2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (≤5.0 × ULN in case of liver metastases).
8. Adequate pancreatic function, including:

   1. Serum total amylase ≤1.5 × ULN.\*
   2. Serum lipase \<1.5 × ULN. \*if total amylase \>1.5 × ULN, but pancreatic amylase is within the ULN, the participant may be enrolled.
9. Acute effects of any prior therapy resolved to baseline severity or to CTCAE Grade \<1 except for AEs that in the Investigator's judgment do not constitute a safety risk for the participant.
10. Systemic anticancer therapy completed within a minimum of 5 half-lives of study enrollment (unless clinically meaningful tumor flare per discretion of the Investigator, in which discussion with the Sponsor is warranted).
11. Evidence of a personally signed and dated informed consent document indicating that the participant (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
12. Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.
13. Pregnancy test for females of childbearing potential negative at Screening or female participants who are not of childbearing potential. Male and female participants of childbearing potential and at risk for pregnancy must agree to use a highly effective method of contraception from the time of Screening, throughout the study and for 3 months after the last dose of assigned treatment, 6 months if female participants.

Exclusion Criteria:

1. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study enrollment. Palliative radiation (\<10 fractions) must have been completed at least 48 hours prior to study enrollment. Stereotactic or small field brain irradiation must have completed at least 2 weeks prior to study enrollment. Whole brain radiation must have completed at least 4 weeks prior to study enrollment. Prior irradiation to \>25% of the bone marrow.
2. Major surgery within 4 weeks prior to enrollment. Minor surgical procedures (eg, port insertion) are not excluded, but sufficient time should have passed for adequate wound healing.
3. Known prior or suspected severe hypersensitivity to study drug or any component in its formulation.
4. Active and clinically significant bacterial, fungal, or viral infection.
5. Clinically significant vascular (both arterial and venous) and non-vascular cardiac conditions (active or within 3 months prior to enrollment), which may include, but are not limited to:

   1. Arterial disease such as cerebral vascular accident/stroke (including transient ischemic attack \[TIA\]), myocardial infarction, unstable angina;
   2. Venous diseases such as cerebral venous thrombosis, symptomatic pulmonary embolism;
   3. Non-vascular cardiac disease such as congestive heart failure (New York Heart Association Classification Class ≥II), second degree or third degree atrioventricular (AV) block (unless paced) or any AV block with PR interval \>220 msec; or ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, bradycardia defined as \<50 beats per minute (bpm) (unless participant is otherwise healthy such as long distance runners, etc.), machine read ECG with QT interval corrected for heart rate (QTc) \>470 msec, or congenital long QT syndrome.
6. History or known presence of interstitial fibrosis, interstitial lung disease (ILD), pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and pulmonary fibrosis.
7. Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the participant inappropriate for enrollment in this study.
8. Evidence of active malignancy (other than current NSCLC, non-melanoma skin cancer, in situ cervical cancer, papillary thyroid cancer, ductal carcinoma in situ \[DCIS\] of the breast or localized and presumed cured prostate cancer) within the last 3 years prior to enrollment.
9. Concurrent use of any of the following food or drugs (consult the Sponsor if in doubt whether a food or a drug falls into any of the categories described below) within 12 days prior to the first dose of lorlatinib:

   1. Known strong cytochrome (CYP)3A inducers (eg, carbamazepine, enzalutamide, mitotane, rifampin, St. John's Wort).
   2. Known strong CYP3A inhibitors (eg, grapefruit juice or grapefruit/grapefruit related citrus fruits \[eg, Seville oranges, pomelos\], boceprevir, cobicistat, clarithromycin, conivaptan, diltiazem, idelalisib, indinavir, itraconazole, ketoconazole, lopinavir, nelfinavir, paritaprevir, posaconazole, ritonavir alone and with elvitegravir or indinavir or lopinavir or paritaprevir or ombitasvir or dasabuvir or saquinavir or tipranavir, telaprevir and voriconazole). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed.
   3. Known CYP3A substrates with narrow therapeutic index, such as pimozide, quinidine, tacrolimus, cyclosporine, sirolimus, alfentanil, fentanyl (including transdermal patch) or ergot alkaloids (ergotamine, dihydroergotamine).
   4. Known permeability glycoprotein (P-gp) substrates with a narrow therapeutic index (eg, digoxin).
10. Participants who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or participants who are Pfizer employees directly involved in the conduct of the study.
11. Participation in other studies involving investigational drug(s) (Phases 1-4) during study participation.
12. Breastfeeding female participants.",,,INTERVENTIONAL
NCT04082598,Antibiotic Therapy in Erupted Tooth Extractions,"Tooth Extraction, Post-Op Complication, Amoxicillin",COMPLETED,"Inclusion Criteria:

* Patients who needed tooth extractions
* Patients older than 18 years
* Patients able to understand and to sign a consent form

Exclusion Criteria:

* General contraindications to oral surgery
* Third molar or impacted tooth extractions
* Patients treated or under treatment with immunosuppressive agents or patients immunocompromised
* Patients treated or under therapy with amino-bisphosphonate and anti-angiogenetic intravenous medications
* Patients who received head and neck irradiation treatments
* Patients who were diagnosed with uncontrolled diabetes
* Patients suffering from renal failure
* Pregnancy and breastfeeding patients
* Patients diagnosed with drug and alcohol addiction
* Patients who suffer from psychiatric disorders
* Patients diagnosed with allergy to penicillin and probiotic",,,INTERVENTIONAL
NCT01734473,Casein Protein and Leucine Supplementation in Chronic Obstructive Pulmonary Disease (COPD),COPD,UNKNOWN,"Inclusion criteria COPD subjects:

* Ability to walk, sit down and stand up independently
* Age 45 years or older
* Ability to lie in supine or elevated position for 5.5 hours
* Diagnosis of moderate to very severe chronic airflow limitation and compliant to the following criteria: Forced Expiratory Volume(FEV1)/Forced Vital Capacity (FVC) \< 0.70 and FEV1 \< 70% of reference FEV1
* Clinically stable condition and not suffering from a respiratory tract infection or exacerbation of their disease (defined as a combination of increased cough, sputum purulence, shortness of breath, systemic symptoms such as fever, and a decrease in FEV1 \> 10% compared with values when clinically stable in the preceding year) at least 4 weeks prior to the first test day
* Shortness of breath on exertion
* Willingness and ability to comply with the protocol, including:

  * Adhering to fasting state from 10 pm ± 2h onwards the day prior to each study visit

Inclusion criteria healthy control subjects:

* Healthy male or female according to the investigator's or appointed staff's judgment
* Ability to walk, sit down and stand up independently
* Age 45 years or older
* Ability to lay in supine or elevated position for 5.5 hours
* No diagnosis of chronic airflow limitation and compliant to the following criteria: FEV1/FVC \> 0.70 and FEV1 ≥ 80% of reference FEV1
* Willingness and ability to comply with the protocol, including:

  * Adhering to fasting state from 10 pm ± 2h onwards the day prior to each study visit

Exclusion Criteria all subjects:

* Any condition that may interfere with the definition 'healthy subject' according to the investigator's judgment (for healthy control group only)
* Established diagnosis of malignancy
* Established diagnosis of Insulin Dependent Diabetes Mellitus
* History of untreated metabolic diseases including hepatic or renal disorder
* Presence of acute illness or metabolically unstable chronic illness
* Recent myocardial infarction (less than 1 year)
* Any other condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient
* BMI of \< 18.5 or ≥ 35 kg/m2
* Dietary or lifestyle characteristics:

  * Use of protein or amino acid containing nutritional supplements within 5 days of first test day
  * Current alcohol or drug abuse
* Indications related to interaction with study products:

  * Known allergy to milk or milk products
* Use of long-term oral corticosteroids or short course of oral corticosteroids 4 weeks preceding first test day
* Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements
* (Possible) pregnancy",,,INTERVENTIONAL
NCT00453167,Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer,Lung Cancer,COMPLETED,"Inclusion Criteria:

1. Histologically or cytologically confirmed SCLC
2. Clinically diagnosed metastatic or recurrent SCLC according to Sixth Edition of the AJCC Cancer Staging Manual
3. At least 18 years old
4. ECOG performance status 0-2
5. Disease status must be that of measurable disease defined as RECIST:Lesions that can be accurately measured in at least one dimension \> 10 mm with chest x-ray, spiral CT scan or physical examination
6. Progression during or after prior first line chemotherapy or chemoradiotherapy.
7. Before study entry, a minimum of 21 days must have elapsed since any prior chemotherapy or radiation
8. No prior radiotherapy to measurable lesion(s) but previous surgery and/or chest radiotherapy for the primary lesion is allowed
9. Adequate major organ function including the following:Hematologic function: WBC ≥ 3,500/mm3 or absolute neutrophil count (ANC) ≥ 1,500/mm3, platelet count ≥ 100,000/mm3Hepatic function: bilirubin ≤ 1.5 x UNL , AST/ALT levels ≤ 2.5 x UNLRenal function: serum creatinine ≤ 1.5mg/dL
10. Patients should sign an informed consent
11. If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine device \[IUD\], birth control pills, or barrier device) during and for 3 months after trial. If male, use of an approved contraceptive method during the study and 3 months afterwards. Females with childbearing potential must have a urine negative hCG test within 7 days prior to the study registration.

Exclusion Criteria:

1. MI within preceding 6 months or symptomatic heart disease including unstable angina, congestive heart failure, or uncontrolled arrhythmia
2. Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complication of study therapy
3. Other malignancy with the past 5 years except adequately treated cutaneous basal cell carcinoma or uterine cervix in situ cancer
4. Pregnant or nursing women
5. Psychiatric disorder that would preclude compliance.
6. Major surgery other than biopsy within the past two weeks.",,,INTERVENTIONAL
NCT04167163,Abaloparatide Before Total Knee Arthroplasty,"Osteoporosis, Arthroplasties, Knee Replacement",COMPLETED,"Inclusion Criteria

1. Post-menopausal women and men age ge ≥ 55 years and scheduled to undergo primary TKA at the University of Wisconsin Total Joint Program.
2. Osteoporosis, i.e., BMD T-score (using female reference data) ≤ -2.5 at the lumbar spine, femoral neck OR total hip or ≤ -1.1 with Vertebral Fracture Assessment confirmed vertebral fracture or history of low-trauma nonvertebral fracture in the past 5 years OR osteopenia, BMD T-score (using female reference data) -1.1 to -2.4 at the lumbar spine, femoral neck or total hip and no prior low-trauma fracture.
3. Serum calcium (albumin-corrected), serum creatinine and Parathyroid(PTH) values all within the normal range and 25(OH)D \> 10 ng/mL.
4. Willing to supplement with daily calcium and/or vitamin D3 at protocol specified doses.
5. Able to provide written informed consent.

Exclusion Criteria

1. Unevaluable distal femur BMD due to hardware or other artifacts.
2. History of bone disorders (e.g., Paget's disease) other than osteoporosis.
3. History of prior external beam or implant radiation therapy involving the skeleton other than radioiodine.
4. History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular, gastrointestinal, endocrine, central nervous system, hematologic or metabolic diseases, or immunologic, emotional and/or psychiatric disturbances that, in opinion of the principal investigator, would compromise study data validity.
5. History of Cushing's disease, growth hormone deficiency or excess, hyperthyroidism, hypo- or hyperparathyroidism or malabsorptive syndromes within the past year.
6. History of significantly impaired renal function (serum creatinine \>2.0 mg/dL. If the serum creatinine is \> 1.5 and ≤ 2.0 mg/dL, the calculated creatinine clearance (Cockcroft-Gault) must be ≥ 37 mL/min.
7. History of nephrolithiasis or urolithiasis within the past five years.
8. History of cancer in prior 5 years (basal cell or squamous skin cancer is permissible).
9. History of osteosarcoma at any time.
10. Patients known to be positive for Hepatitis B, Hepatitis C, HIV-1 or HIV-2.
11. Known hypersensitivity to any of the test materials or related compounds.
12. Prior treatment with PTH- or PTHrP-derived drugs, (ABL, teriparatide or PTH (1-84)).
13. Prior treatment with intravenous bisphosphonates at any time or oral bisphosphonates within the past three years. Patients who had received a short course of oral bisphosphonate therapy (3 months or less) may be enrolled as long as the treatment occurred 6 or more months prior to enrollment.
14. Treatment with fluoride or strontium in the past five years or prior treatment with bone-acting investigational agents at any time.
15. Treatment with calcitonin the past 6 months or denosumab in the past 18 months.
16. Treatment with anticonvulsants affecting vitamin D metabolism (phenobarbital, phenytoin, carbamazepine or primidone) or chronic heparin within the prior 6 months.
17. Treatment with anabolic steroids or calcineurin inhibitors (cyclosporin, tacrolimus)
18. Daily treatment with oral, intranasal or inhaled glucocorticoids in the prior 12 months.
19. Exposure to any investigational drug within 12 months.
20. Consumption of \> 2 alcoholic drinks per day or use of illegal drugs within 12 months of screening.
21. Not suitable for study participation due to other reasons at the investigators discretion.",,,INTERVENTIONAL
NCT05920850,"The SHARED, Project, Lung Cancer Screening for African American Men (AAM)",Lung Cancer Screening,COMPLETED,"Inclusion Criteria:

1. Self-identify as African American or Black males
2. Current smokers of any nicotine-containing products
3. Do not self-report a history of lung cancer symptoms
4. Speaks English

Exclusion Criteria:

1. Do not self-identify as African American males
2. Former smokers
3. Self-report a history of lung cancer symptoms
4. Do not speak English",,,INTERVENTIONAL
NCT03087305,Incidence of SCLN Metastasis in Patients Referred for EBUS-TBNA,Lung Cancer,WITHDRAWN,"Inclusion Criteria:

* All patients age 20yrs or greater referred for EBUS-TBNA with suspicion for primary lung cancer

Exclusion Criteria:

1. Refusal to sign consent
2. Signs of skin infection along the neck
3. Adults who lack the capacity to sign consent.",,,OBSERVATIONAL
NCT06961201,Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase,"Extensive-stage Small Cell Lung Cancer (ES-SCLC), The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy",NOT_YET_RECRUITING,"Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
* Life expectancy of ≥6 months.
* Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) (according to the Veterans Administration Lung Study Group (VALG) staging system).
* Participants must not have previously received systemic chemotherapy for ES-SCLC. For participants who have previously received adjuvant/neoadjuvant chemotherapy for non-metastatic disease with curative intent or concurrent/sequential chemoradiotherapy for locally advanced disease, they are eligible for this study if disease progression occurs \>6 months after the completion of the last treatment.
* Participants who have previously received PD-1/L1 inhibitors in the neoadjuvant setting are allowed to participate in this study after investigator assessment and agreement. Participants who have previously received PD-1/L1 inhibitors in the adjuvant setting or as consolidation therapy after curative chemoradiotherapy are not eligible for this study.
* At least one measurable tumor lesion according to RECIST v1.1.
* Meet the criteria for pre-cachexia or cachexia diagnosis (based on the Fearon diagnostic criteria).

Exclusion Criteria:

* Presence of conditions that may affect gastrointestinal absorption, such as dysphagia, malabsorption, history of gastrectomy, or uncontrollable vomiting; ongoing enteral feeding or parenteral nutrition; or anorexia due to neurological causes, psychiatric conditions, or pain that makes eating difficult.
* Currently taking or planning to take other medications that increase appetite or weight, such as corticosteroids (excluding short-term use of dexamethasone during chemotherapy), androgens, progestogens, thalidomide, olanzapine, anamorelin, or other appetite stimulants.
* Patients with Cushing's syndrome, adrenal or pituitary insufficiency; patients with poorly controlled diabetes mellitus.
* Concurrent enrollment in another clinical trial, unless it is an observational, non-interventional trial or the follow-up period of an interventional study.
* Presence of unresolved toxicities from prior anti-tumor treatments. Unresolved is defined as not having returned to Grade 0 or 1 according to NCI CTCAE Version 5.0 (except for alopecia) or not having returned to the levels specified in the enrollment/exclusion criteria.",,,INTERVENTIONAL
NCT04267237,A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer,Non-small Cell Lung Cancer (NSCLC),WITHDRAWN,"Inclusion Criteria:

* Age \>= 18 years;
* Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) per American Joint Committee on Cancer staging criteria, 8th revised edition;
* Complete R0 resection of Stage II or III NSCLC prior to enrollment and adequate recovery from surgery;
* Pathological evaluation of mediastinal lymph nodes preoperatively or intraoperatively;
* ctDNA (circulating tumor DNA) identified in plasma after resection of Stage II-III NSCLC and prior to start of adjuvant platinum-doublet therapy, as determined by central testing;
* Treatment with at least two cycles of adjuvant platinum-doublet chemotherapy regimens for resected NSCLC;
* No unequivocal evidence of disease after surgery and adjuvant platinum-doublet chemotherapy, as assessed on imaging (computed tomography \[CT\] scan or magnetic resonance imaging \[MRI\]) within 28 days prior to randomization;
* Availability of adequate tumor material;
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1;
* Adequate hematologic and end-organ function;
* Negative HIV test at screening;
* Negative hepatitis B test at screening;
* Negative hepatitis C test at screening.

Exclusion Criteria:

* Participants with a known mutation in exons 18-21 of epidermal growth factor receptor (EGFR) or with a known anaplastic lymphoma kinase (ALK) or reactive oxygen species (ROS) alteration;
* History of malignancy other than disease under study within 5 years prior to enrollment, with the exception of malignancies with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer;
* Induction and neoadjuvant systemic therapy prior to resection of NSCLC;
* Radiotherapy prior to or after resection of NSCLC;
* Prior systemic investigational therapy;
* Prior anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, or a cancer vaccine;
* Treatment with systemic immunostimulatory agents within 6 weeks or 5 drug elimination half-lives, prior to initiation of study treatment;
* Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressive medication during study treatment;
* Treatment with monoamine oxidase inhibitors (MAOIs) within 3 weeks prior to initiation of study treatment or requirement for ongoing treatment with MAOIs;
* Active or history of autoimmune disease or immune deficiency;
* Known primary immunodeficiencies, either cellular or combined T-cell and B-cell immunodeficiencies;
* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan;
* Significant cardiovascular disease;
* Major surgical procedure, other than for diagnosis or for resection of disease under current study, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study;
* Known active or latent tuberculosis infection;
* Recent acute infection;
* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during study treatment or within 5 months after the final dose of study treatment;
* Prior allogeneic stem cell or solid organ transplantation;
* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the participants at high risk from treatment complications;
* Known clinically significant liver disease;
* Previous splenectomy;
* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins;
* Known hypersensitivity to Chinese hamster ovary cell products or any component of the atezolizumab formulation;
* Known allergy or hypersensitivity to any component of RO7198457;
* Pregnant or lactating women.",,,INTERVENTIONAL
NCT05451173,Combining ICI With SBRT or HypoFrx-RT for ES NSCLC,"Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III",NOT_YET_RECRUITING,"Inclusion Criteria:

Key Inclusion Criteria

1. Informed Consent
2. Stage I-III NSCLC per AJCC 8th. ed.
3. Tumor PD-L1 expression ≥1% preferred
4. Tumor sample submission
5. Tumor staging prior to registration
6. Age ≥ 18 years
7. WHO/ECOG PS of 0, 1, or 2
8. Life expectancy ≥12 weeks
9. Adequate organ or bone marrow function
10. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients.

Exclusion Criteria:

Key Exclusion Criteria

1. Mixed small cell and non-small cell lung cancer histology
2. Definitive clinical or radiologic evidence of metastatic disease
3. Patients who received systemic therapy for the current cancer prior to enrollment
4. Thoracic radiotherapy within 5 years with exceptions
5. Major surgery within 28 days prior to enrollment with exception
6. Prior exposure to any anti-PD-1 or anti-PD-L1 antibody
7. History of another primary malignancy with exceptions
8. History of idiopathic pulmonary fibrosis, any pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on chest PET/CT or CT scan
9. Active or prior documented autoimmune disease with exceptions
10. History of primary immunodeficiency
11. History of allogenic organ or tissue transplantation",,,INTERVENTIONAL
NCT06950073,Curatively Intended Thoracic Reirradiation,"Radiotherapy Side Effect, Radiation Toxicity, Oncology, Lung Cancer, Thoracic Cancer",NOT_YET_RECRUITING,"Inclusion Criteria:

* Radiotherapy of thoracic lesion(s) (loco-regional lung cancer recurrence, new primary lung cancer, or solitary oligo metastasis) with the aim of long-term local control.
* Reirradiation type 1 or type 2, i.e. previous radiotherapy to the thorax as per ESTRO-EORTC consensus definition of reirradiation \[Andratschke 2022\]. For the sake of this study, multiple treatments to the lungs will be classified as type 2 reirradiation.
* Verification of malignancy based on biopsy. If no biopsy is available, the decision of reirradiation should be agreed upon in a multidisciplinary conference.
* Available digital dose plan(s) from former radiotherapy course(s) (DICOM files) - note that multiple re-treatments are allowed.
* Adequate lung function to tolerate treatment, at the discretion of the treating physician.
* Ability to complete a radiotherapy course with the aim of local control.
* ECOG Performance status 0-2.
* Estimated life expectancy ≥ 6 months
* Age ≥18 years
* Signed informed consent

Exclusion Criteria:

* Uncontrolled other malignancy.
* The primary and the reirradiation treatment may not be quasi-simultaneous (i.e. the two treatments should be planned independently)
* Pregnancy
* Radiotherapy to a minimum CTV mean dose of 45 Gy for SCLC and 50 Gy for NSCLC and oligometastatic lesions. Treatment schedule according to local protocols and treating physician preference.",,,OBSERVATIONAL
NCT00923884,Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer,"Carcinoma, Non-Small Cell Lung, Carcinoma, Small-Cell Lung",COMPLETED,"* INCLUSION CRITERIA:

  1. Patients 18 years of age and older are eligible.
  2. Histologic diagnosis of primary lung carcinoma. For non small cell lung cancer, patients can be stage I to IV, and receive any treatment (surgical resection, chemotherapy, radiation, molecularly targeted therapy). For small cell lung cancer, patients can be limited or extensive stage and receive any treatment (surgical resection, chemotherapy, radiation, molecularly targeted therapy).
  3. Patients must have a performance status of ECOG 0, 1, 2, or 3 for admission to this protocol.
  4. Patients with a current diagnosis of or a prior history of other cancers may be included onto this protocol.
  5. Patients may have either normal organ function or impaired organ function.

EXCLUSION CRITERIA:

1\. Children will not be eligible.",,,OBSERVATIONAL
NCT01731587,Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer,Non-small Cell Lung Cancer (NSCLC) Stage III,WITHDRAWN,"Inclusion Criteria:

* Histologically or cytologically documented unresectable Stage III NSCLC, as defined by American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) 7th edition (2009) criteria. All histological subtypes are acceptable, including bronchioalveolar carcinomas
* Documented stable disease or objective response, according to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.0, after primary chemo-radiotherapy (either sequential or concomitant) for unresected Stage III disease, within 4 weeks (28 days) prior to enrollment
* Receipt of concomitant or sequential chemo-radiotherapy, consisting of a minimum of two cycles of platinum-based chemotherapy and a minimum radiation dose of greater than equal to 50 Gray. Subjects must have completed the primary thoracic chemo-radiotherapy at least 4 weeks (28 days) and no later than 84 days prior to enrollment. Subjects who received prophylactic brain irradiation as part of primary chemo-radiotherapy are eligible
* Platelet count greater than or equal to 140 \* 10\^9 per liter, white blood cell (WBC) greater than or equal to 2.5 \* 10\^9 per liter, and hemoglobin greater than or equal to 90 gram per liter
* Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1

Additional Inclusion Criteria apply

Exclusion Criteria:

* Pre-therapies:

  * Previous lung cancer specific therapy (including surgery) other than primary chemo-radiotherapy
  * Receipt of immunotherapy within 4 weeks (28 days) prior to enrollment. Note: Subjects who have received monoclonal antibodies for imaging are acceptable
  * Receipt of investigational systemic drugs (including off-label use of approved products) within 4 weeks (28 days) prior to enrollment
* Disease status:

  * Metastatic disease
  * Malignant pleural effusion at initial diagnosis and/or at trial entry
  * Past or current history of neoplasm other than lung carcinoma, except for curatively treated nonmelanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
  * Autoimmune disease
  * A recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; subjects who have hereditary or congenital immunodeficiencies
  * Any preexisting medical condition requiring systemic chronic steroid or immunosuppressive therapy (steroids for the treatment of radiation pneumonitis are allowed)
  * Known Hepatitis B and/or C
  * Active infection at enrollment, including but not limited to, flu-like infections, urinary tract infections, bronchopulmonary infections, etc
* Physiological functions:

  * Clinically significant hepatic dysfunction (that is, alanine aminotransferase \[ALT\] greater than 2.5 times normal upper limit \[ULN\]; or aspartate aminotransferase \[AST\] greater than 2.5 times ULN; or bilirubin greater than or equal to 1.5 \* ULN)
  * Clinically significant renal dysfunction (that is, serum creatinine greater than or equal to 1.5 \* ULN)
  * Clinically significant cardiac disease, for example, New York Heart Association (NYHA) Classes III-IV; uncontrolled angina, uncontrolled arrhythmia or uncontrolled hypertension, myocardial infarction in the previous 6 months as confirmed by an electrocardiogram (ECG)
  * Splenectomy
  * Infectious process that in the opinion of the investigator could compromise the subject's ability to mount an immune response

Additional Exclusion Criteria apply",,,INTERVENTIONAL
NCT00377338,Safety and Accuracy of Alveoscopy in Interstitial Lung Diseases,Respiratory Tract Diseases,COMPLETED,"Inclusion Criteria:

* Healthy volunteers: normal chest X-rays and normal lung function tests
* Patients without parenchymal lung diseases: normal chest computed tomography (CT) scan, normal lung function tests, indication for a bronchoscopy
* Patients with parenchymal lung disease: indication for a bronchoscopy
* Written informed consent for the alveoscopy

Exclusion Criteria:

* Bleeding disorders
* Pulmonary hypertension
* Contraindication for a bronchoscopy
* known hypersensitivity to the fluorescent contrast agent (if required)",,,OBSERVATIONAL
NCT06933758,Temple Health Chest Initiative (THCI 2.0),Chronic Obstructive Pulmonary Disease (COPD),RECRUITING,"Inclusion Criteria:

* 50 to 80 years old
* Screened for early lung cancer using low dose CT imaging

Exclusion Criteria:

* Under 50; over 80 years old
* No lung cancer screening",,,OBSERVATIONAL
NCT02429856,Posterior Cruciate Retaining (PCR) Versus Posterior Cruciate Substituting (PCS) Total Knee Arthroplasty (TKA),"Arthroplasty, Replacement, Knee, Knee Arthroplasty, Total",COMPLETED,"Inclusion Criteria:

* scheduled for primary TKA
* non-inflammatory arthritis
* intact Posterior Cruciate Ligament at the time of surgery

Exclusion Criteria:

* required bone grafting of either the femur or tibia
* varus or valgus deformity of \> 15 degrees
* previous high tibial osteotomy
* unable to understand or comply with the study requirements
* unable to provide signed informed consent",,,INTERVENTIONAL
NCT00293332,"Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery",Lung Cancer,TERMINATED,"DISEASE CHARACTERISTICS:

* Histologically confirmed non-small cell lung cancer

  * No squamous cell carcinoma
  * No histology in close proximity to a major vessel
* Resectable stage IB-IIIA disease
* No CNS or brain metastases

PATIENT CHARACTERISTICS:

* ECOG performance status 0-1
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Hemoglobin ≥ 8.0 g/dL
* Bilirubin normal
* Creatinine ≤ 1.5 mg/dL
* Urine protein:creatinine \< 1.0
* Alkaline phosphatase (AP), AST, and ALT must meet 1 of the following criteria:

  * AP normal AND AST and ALT ≤ 5 times upper limit of normal (ULN)
  * AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN
  * AP ≤ 5 times ULN AND AST and ALT normal
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for at least 3 months after completion of study treatment
* Adequate pulmonary and cardiovascular function to tolerate surgical resection
* No cavitation or history of hemoptysis (i.e., bright red blood ≥ ½ teaspoon)
* No existing peripheral neuropathy ≥ grade 1
* No known history of severe hypersensitivity reaction to drugs formulated with polysorbate 80
* No history of serious systemic disease, including any of the following:

  * Myocardial infarction within the past 6 months
  * Uncontrolled hypertension (i.e., blood pressure \> 150/110 mm Hg on medication)
  * Unstable angina
  * New York Heart Association class II-IV congestive heart failure
  * Unstable symptomatic arrhythmia requiring medication

    * Patients with chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) are eligible
  * Clinically significant peripheral vascular disease (i.e., grade II or higher)
* No history of significant neurological or psychiatric condition
* No known active infection within the past 14 days
* No serious, nonhealing wound, ulcer, or bone fracture
* No evidence of bleeding diathesis or coagulopathy
* No stroke within the past 6 months
* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
* No other serious illness or medical condition
* No active infection
* No other currently active malignancy except nonmelanoma skin cancer

  * Malignancies for which therapy has been completed and are considered to have ≤ 30% chance of risk of relapse are not considered active

PRIOR CONCURRENT THERAPY:

* No prior chemotherapy or VEGF inhibitor
* No prior (i.e., within the past 4 weeks), concurrent, or anticipated participation in another experimental drug study except a Genentech-sponsored bevacizumab cancer study
* No major surgical procedure, open biopsy, or significant traumatic injury within the past 28 days
* No anticipation for major surgical procedure during study treatment
* No fine-needle aspiration or core biopsy within 7 days prior to study entry
* No concurrent full-dose anticoagulation
* No other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy for this cancer",,,INTERVENTIONAL
NCT00533884,Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic,"Neurocognitive Impairment, Delirium, Esophageal Cancer, Head and Neck Cancer, Lung Cancer",COMPLETED,"DISEASE CHARACTERISTICS:

* Newly diagnosed solid tumors of the upper aerodigestive system, including cancers of the head and neck, esophagus, or lung
* Receiving treatment at the Henry-Joyce Cancer Clinic at the Vanderbilt-Ingram Cancer Center
* No known brain metastasis

PATIENT CHARACTERISTICS:

* Able to hear, speak, and understand English
* No prior diagnosis of other cancer except basal cell carcinoma

PRIOR CONCURRENT THERAPY:

* No treatment plans including prophylactic cranial irradiation",,,OBSERVATIONAL
NCT05544929,A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers,"Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms",RECRUITING,"Inclusion Criteria:

* Non-small cell lung cancer with historic PD-L1 ≥ 1%, as determined locally using a clinically accepted assay. Patients must have experienced benefit from previous anti-PD(L)1-containing therapy for at least 4 months based on investigator-assessed disease stability or response prior to developing documented disease progression. Patients must have also received prior platinum-based chemotherapy, either in combination or in sequence with anti-PD-(L)1, unless patient was ineligible to receive such treatment.
* Renal cell carcinoma, clear cell histology, previously treated with anti-PD(L)1-containing therapy and a VEGF targeted therapy as monotherapy or in combination. Patients should have documented disease progression following anti-PD(L)1-containing therapy.
* Cutaneous melanoma, previously treated with anti-PD(L)1-containing therapy. Patients should have documented disease progression following anti-PD(L)1-containing therapy. Patients with BRAF V600-mutant melanoma must have also received prior therapy with a BRAF V600 inhibitor, with or without a MEK inhibitor.
* Ovarian cancer, high-grade serous histology, naïve to anti-PD(L)1 therapy, must have received one prior systemic therapy in platinum-resistant setting.
* Nasopharyngeal carcinoma, non-keratinizing locally advanced recurrent or metastatic. Depending on the study arm, patients may be naïve to anti-PD(L)1 therapy, or previously treated with platinum-based chemotherapy with or without anti-PD-(L)1.
* Locally advanced unresectable or metastatic triple negative breast cancer, ovarian cancer (high-grade serous histology), anal cancer (squamous), MSI-H CRC, esophagogastric cancer, mesothelioma, and HNSCC.
* Locally advanced unresectable or metastatic anal cancer (squamous), thymic carcinoma, MSI-H CRC, esophagogastric cancer, mesothelioma, and HNSCC, all naïve to anti-PD(L)1 therapy and for whom anti PD(L)1 therapy is not available.
* Triple negative breast cancer with historic PD-L1 CPS ≥ 1%, must have received at least one line of chemotherapy. In addition, these patients must have previously received sacituzumab govitecan, and in the case of a BRCA mutation a PARP inhibitor, if these treatments are locally approved and accessible to the patient.

Exclusion Criteria:

* Impaired cardiac function or clinically significant cardiac disease.
* Use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of study.
* History of severe hypersensitivity reactions to any ingredient of study drug(s) and other mAbs and/or their excipients.
* Active, known or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur may be considered. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.
* Any evidence of interstitial lung disease (ILD) or pneumonitis, or a prior history of ILD or non-infectious pneumonitis requiring high-dose glucocorticoids.
* Patients who discontinued prior anti-PD-(L)1 therapy due to an anti-PD-(L)1-related toxicity (applicable to the KFA115 in combination with pembrolizumab treatment arms).
* Patients with symptomatic peripheral neuropathy limiting instrumental activities of daily living.

Other protocol-defined inclusion/exclusion criteria may apply",,,INTERVENTIONAL
NCT05794529,Lung Tumor Protein Synthesis Rates in Lung Cancer Patients,Lung Cancer,RECRUITING,"Inclusion Criteria:

1. Aged 18-65 years
2. Compos mentis
3. Diagnosed with lung cancer, with treatment requiring a thoracotomy or VATS lobectomy

Exclusion Criteria:

1. Neoadjuvant chemo- or radiotherapy in the past four weeks
2. Use of systemic steroids in the past four week
3. Insulin-dependent diabetes mellitus
4. Pregnancy",,,OBSERVATIONAL
NCT05997550,The Effect of Pursed Lip Breathing Exercise and Laughter Therapy Individuals With The COPD,Chronic Obstructive Pulmonary Disease,NOT_YET_RECRUITING,"Inclusion Criteria:

* Those aged 40 and over,
* He was diagnosed with COPD as a result of medical history, physical examination and pulmonary function tests, and his CAT score is 10 and above according to the COPD Unified Assessment\* of the GOLD guide; In Group B and D (1),
* There is no diagnosis of a disease that may affect the cognitive state,
* Not having a diagnosis of a physical or mental illness that will prevent communication, and able to use a telephone.
* Individuals who agree to participate in the research are included in the study

Non-Inclusion Criteria:

Those who have difficulty in verbal communication (intubation, tracheostomy, delirium, etc.)

* With a CAT score of less than 10 and in Groups A and C according to the COPD Combined Assessment\* of the GOLD guide,
* Having a disorder that disrupts the cognitive process such as schizophrenia or dementia
* Alcohol, substance addiction,
* Laughter therapy was not deemed appropriate due to the diagnosis of abdominal surgery, uncontrolled hypertension, glaucoma, abdominal hernia, epilepsy in the last three months,
* Using complementary and integrative treatments such as acupuncture, meditation, yoga, massage, relaxation exercises,
* Patients who do not agree to participate in the study are excluded from the study.

Exclusion criteria

* Not complying with pursed lip breathing exercise and laughter therapy and program,
* Developing a disease that may affect the health status or a condition requiring hospitalization (COPD exacerbation, etc.) during the 12-week period during which the research will take place,
* Changes in bronchodilator and oxygen therapy regimens,
* A situation that is not suitable for laughter therapy due to the diagnosis of surgery in the abdominal region, uncontrollable hypertension, glaucoma, abdominal hernia, epilepsy,
* Patients who want to withdraw from the study are excluded from the study.",,,INTERVENTIONAL
NCT06116786,A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer,"Carcinoma, Non-small-Cell Lung",RECRUITING,"Inclusion Criteria:

* Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC)
* Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor \[EGFR\], anaplastic lymphoma kinase \[ALK\], c-ros oncogene 1 \[ROS1\], v-raf murine sarcoma viral oncogene homolog B1 \[BRAF\]) must have received all approved targeted therapies and have progressed
* Part 2: No targetable mutations (for example, EGFR \[epidermal growth factor receptor\], ALK \[anaplastic lymphoma kinase\], ROS1\[c-ros oncogene 1\], and BRAF \[B-Raf proto-oncogene, serine/threonine kinase\])
* Part 1 and Cohort A of part 2: Must have been treated with (a) anti-programmed death protein 1 (anti-PD-1) or programmed cell death ligand 1 (PD-L1) therapy and (b) platinum-based chemotherapy
* For Cohort B of Part 2: Previously treated with anti-PD-1/PD-L1 therapy for metastatic disease as the prior line of therapy
* For Cohort C of Part 2: Treatment naïve
* Adequate organ function

Exclusion Criteria:

* Active central nervous system (CNS) disease involvement
* Active autoimmune disease
* Active infection
* History of solid organ or hematologic stem cell transplantation",,,INTERVENTIONAL
NCT02456246,Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT,Non Small Cell Lung Cancer (NSCLC),COMPLETED,"Inclusion Criteria:

1. Age ≥ 18 years
2. Must have been treated at or plan to be treated at Princess Margaret Cancer Centre with SBRT for an early-stage NSCLC (T1N0M0; T2N0M0; or T3N0M0 chest wall primary tumours only) and are either:

   1. Prior to treatment with lung SBRT (for Cohort 1)
   2. Have radiographic findings on that are felt to be related to fibrosis at any time point following lung SBRT
   3. Have radiographic findings on CT that are suspicious for recurrence at any time point following lung SBRT
3. Ability to provide written informed consent to participate in the study

Exclusion Criteria:

1. Previous systemic therapy
2. Previous thoracic radiotherapy(excluding the index lung SBRT treatment)
3. Active malignancy other than lung cancer
4. Unable to remain supine for more than 30 minutes
5. If taking the drug Antabuse
6. Pregnancy",,,INTERVENTIONAL
NCT05176483,Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors,"Renal Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer, Urothelial Carcinoma, Solid Tumor, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma",ACTIVE_NOT_RECRUITING,"Inclusion Criteria:

* Cytologically or histologically confirmed solid tumor that is unresectable, locally advanced or metastatic.
* Dose-Escalation Cohorts: Subjects with a solid tumor that is unresectable or metastatic and for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective.
* Expansion Cohort 1 (ccRCC): Subjects with unresectable advanced or metastatic RCC with a clear cell component who have not received prior systemic therapy.

  * Note: Prior non-VEGF targeted adjuvant or neoadjuvant is allowed if disease recurrence occurred 6 months after the last dose.
* Expansion Cohort 2 (ccRCC): Subjects with unresectable advanced or metastatic RCC with a clear cell component.

  * Must have radiographically progressed after a combination therapy consisting of a PD-1/PD-L1 targeting mAb with a VEGFR-TKI or a PD-1 targeting mAb with a CTLA-4 mAb as the preceding line of therapy.
  * Must have received no more than one prior systemic anticancer therapy for unresectable advanced or metastatic renal cell carcinoma.
* Expansion Cohort 3 (mCRPC): Men with metastatic adenocarcinoma of the prostate.

  * Must have progressed during or after one novel hormone therapy (NHT) given for castration-sensitive locally advanced (T3 or T4) or metastatic castration-sensitive prostate cancer (CSPC), M0 CRPC, or mCRPC.
* Expansion Cohort 4 (UC, ICI-naive): Subjects with histologically confirmed unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including the renal pelvis, ureter, urinary bladder, or urethra).

  * Must have progressed during or after prior first-line platinum-based combination therapy, including subjects who received prior neoadjuvant or adjuvant platinum-containing therapy with disease recurrence \< 12 months from the end of last therapy.
  * Must have received no more than 1 prior line of systemic anticancer therapy for unresectable, locally advanced or metastatic disease.
* Expansion Cohort 5 (UC, ICI-experienced): Subjects with histologically confirmed unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including the renal pelvis, ureter, urinary bladder, or urethra).

  * Must have progressed during or after prior PD-1/PD-L1 targeting ICI therapy given as monotherapy, combination therapy, maintenance therapy or adjuvant therapy.
  * Must have received no more than 2 prior lines of systemic anticancer therapy for unresectable advanced or metastatic disease.
* Expansion Cohort 6 (nccRCC): Subjects with unresectable advanced or metastatic nccRCC of the following subtypes: Papillary, unclassified RCC, and translocation-associated, FH deficient and SDH deficient. Among the eligible histologic subtypes, sarcomatoid features are allowed.

  * No prior systemic anticancer therapy is allowed except adjuvant or neoadjuvant therapy if disease recurrence occurred at least 6 months after the last dose.
* Expansion Cohort 7 (HCC): Subjects with locally advanced, or metastatic and/or unresectable HCC that is not amenable to curative treatment or locoregional therapy.
* Expansion Cohort 8 (NSCLC): Subjects with Stage IV non-squamous NSCLC with positive PD-L1 expression (tumor proportion score \[TPS\] 1-49%) and without prior systemic anticancer therapy for metastatic disease.
* Expansion Cohort 9 (NSCLC): Subjects with Stage IV non-squamous NSCLC who have radiologically progressed following treatment with one prior immune checkpoint inhibitor (anti-PD-1 or anti-PD-L1) for metastatic disease.
* Expansion Cohort 10 (CRC): Subjects with histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the colon or rectum.
* Expansion Cohort 11 (HNSCC): Subject with inoperable, refractory, recurrent or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx. PD-L1 combined positive score (CPS) ≥1.
* Expansion Cohort 12 (ccRCC): Subjects with unresectable advance or metastatic RCC with a clear cell component, including subjects who also have a sacromatoid feature.

  * Must have received no more than two prior lines of systemic anticancer therapy for unresectable advanced or metastatic renal cell carcinoma
* Expansion Cohort 13 (ccRCC): Subjects with unresectable advanced or metastatic RCC with a clear component, including subjects who also have a sacromatoid feature.
* For all Expansion Cohorts except Cohort 3: Measurable disease per RECIST 1.1 as determined by the Investigator.
* For Expansion Cohorts 1 - 11 Only: Archival tumor tissue material, if available, or fresh tumor tissue if it can be safely obtained.
* Recovery to baseline or ≤ Grade 1 common terminology criteria for adverse events (CTCAE) v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and/or stable on supportive therapy.
* Karnofsky Performance Status (KPS) ≥ 70%.
* Adequate organ and marrow function.
* Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception.
* Female subjects of childbearing potential must not be pregnant at screening.

Exclusion Criteria:

* For all Dose-Escalation cohorts: Prior treatment with XL092. For all Expansion Cohorts: Prior treatment with XL092, nivolumab, ipilimumab or relatlimab with the following exceptions: Prior PD-1/PD-L1, LAG-3 and CTLA-4 targeting therapy for locally advanced or metastatic disease is allowed for Cohort 2 (ccRCC), Cohort 5 (UC), Cohort 9 (NSCLC), and Cohort 12 (ccRCC), and prior treatment in the neoadjuvant or adjuvant setting is allowed for Cohort 13 (ccRCC).
* For all Dose-Escalation Cohorts and Expansion Cohort 2 (ccRCC), 3 (mCRPC), Cohort 5 (UC), Cohort 9 (NSCLC), Cohort 10 (CRC), and Cohort 12: Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.
* For Cohort 3 (mCRPC): Receipt of abiraterone within 1 week; cyproterone within 10 days; or receipt of flutamide, nilutamide, bicalutamide, enzalutamide, or other androgen receptor inhibitors within 2 weeks before first dose of study treatment.
* For all Dose-Escalation Cohorts and Expansion Cohort 2 (ccRCC), Cohort 3 (mCRPC), Cohort 5 (UC), Cohort 9 (NSCLC) and Cohort 10 (CRC), and Cohort 12: Receipt of any type of anticancer antibody or systemic chemotherapy within 4 weeks before first dose of study treatment.
* Any complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment.
* Prior external radiation therapy for bone metastasis within 2 weeks, for other tumor sites within 4 weeks, and prior radium-223 therapy within 6 weeks before first dose of study treatment, unless otherwise specified.
* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.
* Concomitant anticoagulation with oral anticoagulants, except for specified direct factor Xa inhibitors.
* Administration of a live, attenuated vaccine within 30 days prior to first dose.
* Uncontrolled, significant intercurrent or recent illness.
* Corrected QT interval calculated by the Fridericia formula (QTcF) \> 460 ms for females and \> 450 ms for males per electrocardiogram (ECG) within 14 days before first dose of study treatment.
* Subjects with inadequately treated adrenal insufficiency.
* Pregnant or lactating females.
* Any other active malignancy within two years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy. Incidentally diagnosed prostate cancer is allowed if assessed as stage ≤ T2N0M0 and Gleason score ≤ 6.
* For Cohort 2 (ccRCC, 2L): Receipt of a prior triplet therapy including a VEGFR-TKI, a PD1 targeting mAb, and a CTLA-4 mAb.
* For Cohort 3 (mCRPC): Receipt of a taxane-based chemotherapy for mCRPC.
* For Cohort 4 (UC, ICI-naïve): Subjects who have had recurrence within the 6 months of completing adjuvant anti-PD-(L)1 treatment.
* For Cohort 6 (nccRCC, 1L): Subjects with chromophobe, renal medullary carcinoma, or pure collecting duct nccRCC.
* For Cohort 7 (HCC):

  * Documented hepatic encephalopathy (HE) within 6 months before the first dose.
  * Clinically meaningful ascites (ie, ascites requiring paracentesis or escalation in diuretics) within 6 months before randomization.
  * Subjects who have received any local anticancer therapy including surgery, PEI, RFA, MWA, transarterial chemoembolization (TACE), or transarterial radioembolization (TARE) within 28 days prior to first dose.
  * Subjects with known fibrolamellar carcinoma, sarcomatoid HCC, or mixed hepatocellular cholangiocarcinoma
* For Cohort 10 (CRC, 2L+): Receipt of prior therapy with regorafenib and/or trifluridine + tipiracil (TAS-102).
* For Cohort 11 (HNSCC): Primary tumor site of the nasopharyngeal area.
* For Cohorts 1 (ccRCC, 1L), 2 (ccRCC, 2L), 4, 5 (UC), 7 (HCC), 8 (NSCLC 1L PD-L1 low), 9 (NSCLC, 2L+), 10 (CRC, MSS, 2L+), and 11 (HNSCC):

  * Troponin T (TnT) or I (TnI) \> 2 × institutional ULN.

Note: Additional Inclusion and Exclusion criteria may apply.",,,INTERVENTIONAL
NCT04695379,Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection,Myasthenia Gravis,COMPLETED,"Inclusion Criteria:

* 1\. Child or adult patients, living or deceased, presenting or having presented a myasthenic syndrome and a COVID-19 infection 2. Myasthenic syndrome is established by:

  * Either the presence of a specific antibody
  * Either the presence of specific electrophysiological abnormalities
  * Either an evocative symptomatology improved by a therapeutic test with an acetylcholinesterase inhibitor
  * Either one or two pathogenic mutation (s) in a gene involved in congenital myasthenic syndromes (dominant or recessive disease).

    3\. COVID-19 infection is established by
  * Either a positive PCR test
  * Or a specific chest scanner
  * Either a positive serology
  * Either a clinical syndrome of COVID-19, validated by a committee of experts. 4. Patients affiliated or beneficiaries of a social security scheme 5. For living patients: patients who have been informed of the study and have not exercised their right of opposition or parents or holders of parental authority who have been informed of the study and have not exercised their right opposition.

For deceased patients: beneficiaries or parents / holders of parental authority having been informed of the study and not having exercised their right of objection.

Exclusion Criteria:

1\. Persons placed under judicial protection",,,OBSERVATIONAL
NCT00896909,HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598,Lung Cancer,COMPLETED,"DISEASE CHARACTERISTICS:

* Diagnosis of non-small cell lung cancer meeting ≥ 1 of the following criteria:

  * Recurrent disease
  * Stage IIIB with pleural or pericardial effusion
  * Stage IV disease
* Treated on protocol ECOG-2598

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics",,,OBSERVATIONAL
NCT04062253,Addressing the Cascade of Care in Vulnerable Populations With Poor Access to Healthcare in Madrid,"HCV Infection, HIV Infections, Drug Use, HBV (Hepatitis B Virus), Viral Hepatitis",COMPLETED,"Inclusion Criteria:

* Vulnerable populations who include one or more of the following:

  * Persons who inject drugs,
  * Homeless,
  * Migrants
  * Sex workers

Exclusion Criteria:

* Not signing inform consent.",,,OBSERVATIONAL
NCT06849518,Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer,Lung Cancer (NSCLC),RECRUITING,"Inclusion Criteria:

1. All patients with a diagnosis of stage IV or inoperable stage IIIB NSCLC without planned primary radiation therapy undergoing anti-PD-1/L1 based ICI treatment.
2. Chemo-immune or dual anti-PD-1/L1 with anti-CTLA-4 based regimens are eligible as long as receiving an anti-PD-1/L1 monoclonal antibody.
3. A documented informed consent will be obtained prior to inclusion in the study. All discussions with patients will be held in strictest confidence and out of earshot of the general public. Patients will be fully informed that their participation in the study is voluntary. Patients may decline to be part of the study. Their decision to participate in the study will not affect the care they receive.

Exclusion Criteria:

1. No anti-PD-1/L1 monoclonal antibody treatment.
2. Planned primary radiation therapy.
3. Small-cell lung cancer histology.",,,INTERVENTIONAL
NCT06224010,Respiratory Drive and Inspiratory Effort in COVID-19 Associated ARDS,"ARDS, Human, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome, Respiratory Effort-Related Arousal, Weaning Failure, Mechanical Ventilation Complication, Acute Hypoxic Respiratory Failure",COMPLETED,"Inclusion Criteria:

* Patients with a diagnosis of acute respiratory distress syndrome based on the Berlin criteria.
* Patients with ARDS due to confirmed COVID-19 through real-time RT-PCR on nasopharyngeal swabs or lower respiratory tract aspirates.
* Patients who had received invasive mechanical ventilation for more than 72 hours.
* Patients who were candidates for assisted ventilation.

Readiness for assisted ventilation, which was defined by the following criteria:

1. Improvement of the condition leading to acute respiratory failure.
2. Positive end-expiratory pressure lower than 10 cmH2O and inspiratory oxygen fraction lower than 0.5.
3. Richmond agitation sedation scale score between 0 and -3.
4. Ability to trigger the ventilator, i.e., decrease pressure airway opening by more than 3-4 cmH2O during a brief (5-10 seconds) end-expiratory occlusion test.

   * Hemodynamic stability without vasopressor or inotropes, except for dobutamine and norepinephrine infusion below certain thresholds (dobutamine \<5 gamma/Kg/min and norepinephrine \<0.3 gamma/Kg/min).
   * Normothermia.

Exclusion Criteria:

* Patients affected by neurological or neuromuscular pathology and/or known phrenic nerve dysfunction.
* Patients with any contraindication to the insertion of a nasogastric tube, such as recent upper gastrointestinal surgery or esophageal varices.
* Patients \< 18 years old",,,OBSERVATIONAL
NCT00062010,"Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer",Lung Cancer,COMPLETED,"Inclusion Criteria

* Histologically or cytologically confirmed recurrent small cell lung cancer (SCLC) with clinically confirmed measurable disease
* Age 18 and over
* ECOG Performance status 0-3
* Absolute neutrophil count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
* Bilirubin no greater than 1.5 mg/dL
* AST no greater than 2 times upper limit of normal (ULN)
* Creatinine no greater than 1.5 mg/dL
* Triglycerides no greater than 1.5 times ULN
* Patients must have had prior chemotherapy treatment for SCLC, and toxicities must have resolved to less than or equal to grade 1
* Women of childbearing potential and sexually active males are strongly encouraged to use an accepted and effective method of contraception.

Exclusion Criteria

* History of another neoplasm other than SCLC except for non-metastatic, non-melanoma skin cancers, carcinoma in situ of the cervix, or cancer cured by surgery or small field radiotherapy at least 5 years before registration
* Pregnant or nursing, with a negative pregnancy test within 2 weeks prior to registration
* Severe depression requiring medication
* Use of the following drugs within 4 weeks prior to registration: carbamazepine, ethanol, tetracycline, doxycycline, minocycline, topical acne products containing Retin-A, vitamin A, cisplatin, ketoconazole, phenytoin or other antiepileptic drugs
* Use of GM-CSF or G-CSF within 4 weeks prior to registration
* Prior paclitaxel or interferon therapy
* Radiation therapy within 60 days prior to registration
* Chemotherapy within 60 days prior to registration",,,INTERVENTIONAL
NCT02090166,Lung Cancer Detection by Measuring Monocyte Activity,Lung Cancer,UNKNOWN,"Inclusion Criteria

1. Subject signed the informed consent.
2. Subject is between 18 to 90 years old.
3. Lung cancer diagnosis before any treatment

Exclusion Criteria

1. Lung cancer patients
2. Subject has been previously treated for any type of malignant or benign tumor (for example: colon or uterus polyps removal).
3. Subject has active infection or inflammation determined clinically at screening.
4. Subject is currently treated with concomitant medication related directly or can affect the immune system.
5. Subject lactating or undergoing fertility treatment.
6. Subject has impaired judgment.
7. Known positive HIV, hepatitis B, or hepatitis C, autoimmune disease.
8. Known history of a significant medical disorder, which in the investigators' judgment contraindicates the patient's participation.
9. Known hypersensitivity and/or allergy
10. Drug or alcohol abuse (by history).
11. Subject is participating in any other clinical trial, drug or device study within 30 days prior sample collection
12. Relatives of the study investigators or employees of the study investigators are not allowed to participate in the study

    \-",,,INTERVENTIONAL
NCT00864266,Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer,Non Small Cell Lung Carcinoma,COMPLETED,"Inclusion Criteria:

* Histological diagnosis of non-small-cell lung cancer (NSCLC)
* Obtention of a biopsy of the tumour according to the procedure defined in the protocol
* NSCLC of any stage to be treated by standard conventional first-line chemotherapy, as defined in the ELCWP guidelines (www.elcwp.org)
* Presence of at least one assessable lesion
* Availability for participating in the detailed follow-up of the protocol
* Signed informed consent.
* Age above 18 years

Exclusion Criteria:

* Patient who was previously treated with chemotherapy for NSCLC or who has any contra-indication precluding the administration of conventional chemotherapy for NSCLC
* NSCLC treated by exclusive surgery or radiotherapy
* A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or of the bladder or cured malignant tumour (more than 5-year disease free interval)",,,INTERVENTIONAL
NCT03294746,Imaging Biomarker in Cancer Drug Induced ILD,Drug Induced Interstitial Lung Disease (DIILD) Cancer Patients,UNKNOWN,"Inclusion Criteria:

* Age ≥ 18 years
* World health organization (WHO) performance status 0-2
* Life expectancy \> 6 months
* Proven cancer diagnosis in a patient actively undergoing anti-cancer therapy
* New onset symptoms (e.g. cough, fever, dyspnoea, and hypoxia) at any time during or within 4 weeks of the last dose of anti-cancer treatment
* New onset radiological (CXR or CT) abnormalities within the lungs at any time during or within 4 weeks of the last dose of anti-cancer treatment (e.g. diffuse lung changes, infiltrative opacification in the periphery of the lung or ground glass changes) with a locally reviewed diagnosis of DIILD as the most likely explanation for the radiological abnormalities.
* Treatment for DIILD planned (e.g. drug withdrawal, interruption +/- supportive therapy including corticosteroids, oxygen, bronchodilators etc.). Concomitant treatment with antibiotics, anticoagulants etc. is permitted pending results of investigations for differential diagnoses.
* Able to undergo pulmonary function tests (at a minimum spirometry and gas transfer (DLCO))
* Patients enrolled on other anti-cancer investigational trials are permitted at investigator discretion
* Informed written consent obtained according to national/local regulations
* Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 14 days before study registration

Exclusion Criteria:

* Clinically suspected or confirmed radiological features of any malignancy involving the lungs at the time of study registration
* Claustrophobia, or inability to undergo non-contrast CT examination
* Known or suspected non-drug related ILD (e.g. lung abnormalities due to other causes such as occupational exposure)
* Previous extensive thoracic surgery (e.g. lobectomy)
* Clinical, radiological or microbiological evidence of active lower respiratory tract infection
* Currently active, clinically significant heart disease, such as uncontrolled class 3 or 4 congestive heart failure defined by the New York Heart Association Functional Classification
* Any medical, psychological, sociological or geographical condition that could affect participation in the study and compliance with the study protocol",,,INTERVENTIONAL
NCT02864394,Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033),"Carcinoma, Non-Small-Cell Lung",COMPLETED,"Inclusion Criteria:

* Chinese participants must be born, raised, and reside in China
* Has a histologically or cytologically confirmed diagnosis of stage IIIB/IV or recurrent NSCLC and have at least one measurable lesion as defined by RECIST 1.1
* Has a life expectancy of ≥3 months
* Has progression of disease (investigator determined) per RECIST 1.1 after treatment with at least two cycles of a platinum-containing doublet
* Has documentation of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocation status
* Participants with an EGFR sensitizing mutation tumor will be excluded
* Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 within 10 days prior to study start
* Has provided archival tumor tissue sample or newly obtained formalin fixed tumor tissue from a recent biopsy of a tumor lesion not previously irradiated
* Has a PD-L1 positive tumor as determined by immunohistochemistry at a central laboratory
* Has resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia)
* Has recovered from the toxicity and/or complications of any recent major surgery or radiation therapy
* Females must not be pregnant (negative urine or serum human chorionic gonadotropin test within 72 hours prior to receiving the first dose of study medication)
* Female and male participants of reproductive potential must agree to use adequate contraception starting with the first dose of study therapy through 120 days after the last dose of pembrolizumab (MK-3475) or 180 days after the last dose of docetaxel

Exclusion Criteria:

* Has received prior therapy with docetaxel for NSCLC
* Is currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study treatment
* Is receiving systemic steroid therapy within 3 days prior to the first dose of study treatment or receiving any other form of immunosuppressive
* Is expected to require any other form of systemic or localized antineoplastic therapy while on study including maintenance therapy with another agent for NSCLC or radiation therapy
* Has received prior systemic cytotoxic chemotherapy, antineoplastic biological therapy (e.g., cetuximab), any other agents used as systemic treatment for cancer, or major surgery within 3 weeks of the first dose of study treatment; received thoracic radiation therapy of \> 30 Gray Units (Gy) within 6 months of the first dose of study treatment; received prior ALK-directed tyrosine kinase inhibitor therapy or completed palliative radiotherapy of 30 Gy or less within 7 days of the first dose of study treatment
* Has received prior therapy with an anti-programmed cell death 1 (anti-PD-1), anti-PD-L1, anti-PD-L2, with an agent directed to an agonist or antagonist T-cell check point receptor, or if the participant has previously participated in Merck sponsored clinical trials evaluating pembrolizumab (MK-3475)
* Has a known additional malignancy that is progressing or requires active treatment, with the exception of early stage cancers, treated with curative intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy
* Has known active central nervous system metastases and/or carcinomatous meningitis
* Has active autoimmune disease that has required systemic treatment in past 2 years
* Has had an allogeneic tissue/solid organ transplant
* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
* Has received or will receive a live vaccine within 30 days prior to the first administration of study medication
* Has an active infection requiring intravenous systemic therapy
* Has known history of Human Immunodeficiency Virus (HIV) (HIV ½ antibodies)
* Has known active Hepatitis B or C
* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
* Is, at the time of signing informed consent, a regular user (including ""recreational use"") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol)
* Is pregnant or breastfeeding, or expecting to conceive or father children starting with the screening visit (Visit 1) through 120 days after the last dose of pembrolizumab (MK-3475) or 180 days after the last dose of docetaxel
* Requires treatment with a strong inhibitor of Cytochrome P450 3A4",,,INTERVENTIONAL
NCT03088813,Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer,Small Cell Lung Cancer,COMPLETED,"Inclusion Criteria:

* At least 18 years of age.
* Able to understand and provide an informed consent
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Life expectancy \>12 weeks
* Histopathologically or cytologically confirmed small cell lung cancer
* Evaluable disease as defined by RECIST Version 1.1 guidelines (patients with non measurable lesions only are eligible).
* Radiologically confirmed progression on or after first-line platinum based chemotherapy (carboplatin or cisplatin), or chemo-radiation including platinum-based chemotherapy for treatment of limited or extensive stage Small Cell Lung Cancer (SCLC). In addition to platinum-based regimen, one line of immunotherapy as monotherapy or in combination, in first or in second line setting is allowed.
* Recovered from the effects of any prior chemotherapy, surgery, radiotherapy or other anti-neoplastic therapy (recovered to Grade 1 or better, with the exception of alopecia, peripheral neuropathy, or ototoxicity).
* Adequate bone marrow reserves
* Adequate hepatic function
* Adequate renal function
* Electrocardiogram during the Screening period without any clinically significant findings, per investigator's assessment
* Patients with certain types of asymptomatic CNS metastases that meet ALL the following criteria are eligible.

  1. Patients with asymptomatic CNS metastases prior to enrollment
  2. Prior radiation for CNS metastatic disease is completed ≥4 weeks prior to enrollment
  3. CNS metastases that are stable or have decreased according to the post radiation follow-up scan that is conducted at least 4 weeks after completion of radiation treatment for CNS lesion.
  4. Patients have discontinued corticosteroids or are on stable low-dose steroids (prednisone or equivalent 10 mg daily or less) for at least 1 week after completion of radiation for CNS lesion prior to enrollment.

Exclusion Criteria

* Any medical or social condition deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results
* Pregnant or breast feeding;
* Patients with large cell neuroendocrine lung carcinoma.
* Patients who have received prior topoisomerase I inhibitor treatment, retreatment with platinum-based regimen, antibody-drug conjugates or molecular targeted agents, more than one line of immunotherapy, or any other additional regimen of prior cytotoxic chemotherapy.
* Patients with the symptomatic Central Nervous System (CNS) metastasis and/or who have developed new or progressive brain metastasis within 3 months following prophylactic and/or therapeutic cranial radiation (whole brain stereotactic radiation).
* Patients with carcinomatous meningitis.
* Unable to discontinue the use of strong CYP3A4 or UGT1A1 inhibitors at least 1 week or strong CYP3A4 inducers at least 2 weeks prior to receiving the first dose of irinotecan liposome injection.
* Have a previous or concurrent cancer that is distinct in primary (non-pulmonary) site or SCLC histology
* Investigational therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is less, prior to the first scheduled day of dosing in this study.
* Severe cardiovascular and pulmonary diseases
* New York Heart Association Class III or IV congestive heart failure, ventricular arrhythmias, or uncontrolled blood pressure.
* Active infection
* Known hypersensitivity to any of the components of irinotecan liposome injection, other liposomal products, or topotecan.
* Clinically significant gastrointestinal disorder including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea \> grade 1.",,,INTERVENTIONAL
NCT03603652,NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung,"Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma",TERMINATED,"Inclusion Criteria:

1. Signed informed consent.
2. Patients ≥ 18 years old.
3. Performance status 0-2 via ECOG (Eastern Cooperative Oncology Group) classification.
4. Willing to fulfill all follow-up visit requirements.
5. Medically inoperable primary soft tissue lesion of the lung or patient election not to have surgery. (Medically inoperable is defined per the following indicators: post op predictive FEV1 (forced expiratory volume in 1 second) \< 40%; DLCO (diffusing capacity of the lung for carbon monoxide) \< 40%; hypoxemia or hypercapnia diabetes with end-organ damage; or severe cerebral, cardiovascular, peripheral vascular disease, or chronic heart disease)
6. One soft tissue lesion ≤ 2 cm in the outer two thirds of the lung and not closer than 1 cm to the pleura.

   (Outer two thirds of the lung is defined as peripheral beyond the segmental airway, past the segmental bronchi, such that proximal endobronchial soft tissue lesions are avoided; soft tissue lesions should not be contiguous with the pleura)
7. Radiographic resolution of pneumonia

Exclusion Criteria:

1. Scheduled concurrent procedure for the target soft tissue lesion other than those that are lung related.
2. Pregnant or breastfeeding.
3. Physical or psychological condition that would impair study participation.
4. Patients with uncorrectable coagulography at time of screening.
5. Patient with implantable devices, including pacemakers or other electronic implants.
6. Prior pneumonectomy or bronchiectasis.
7. Severe neuromuscular disease.
8. Platelet count ≤ 50,000/mm3.
9. ASA (American Society of Anesthesiologists) score of ≥ 4.
10. Inability to tolerate anesthesia.
11. Expected survival less than 6 months.
12. Clinically significant hypertension.
13. Chronic ventilator support, which uses bi-level positive airway pressure (PAP).
14. Endobronchial soft tissue lesions proximal to the segmental airways",,,INTERVENTIONAL
NCT02412384,The Detection of Circulating Tumor Cells (CTCs) in Patients With Lung Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment,"Neoplastic Cells, Circulating",COMPLETED,"Inclusion Criteria:

1. Age:18-75
2. Karnofsky performance status \>60
3. Diagnosis of lung cancer based on histology or the current accepted radiological measures.
4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ
5. Will receive cryosurgery and/or DC-CIK treatment
6. Life expectancy: Greater than 3 months
7. Patients' routine blood test, liver function and kidney function have no obvious abnormalities
8. Ability to understand the study protocol and a willingness to sign a written informed consent document

Exclusion Criteria:

1. Patients with other primary tumor except lung cancer
2. History of coagulation disorders or anemia",,,OBSERVATIONAL
NCT05031533,Dose-painting Radiation for LA-NSCLC,"Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage II",RECRUITING,"Inclusion Criteria:

1. The patient or the legal representative of the patient can sign a written informed consent, and can understand and agree to follow the research requirements;
2. The age at the time of signing the informed consent form is between 18 and 75 years old;
3. It is diagnosed as non-small cell lung cancer by histology, and is suitable for radical radiotherapy:
4. Stage II-Ⅲ (AJCC 8th edition \[Rice et al., 2017\]) inoperable NSCLC patients (not medically suitable for surgery or refuse surgical intervention);
5. Measurable lesions that meet the definition of RECISTv1.1;
6. ECOG physical status ≤ 2;
7. Survival expectancy ≥ 3 months;
8. Hemoglobin ≥100g/L, WBC≥4×109/L, platelet ≥100×109/L (or follow the standards of each center);
9. Liver function: ALT, AST\<1.5 times the upper limit of normal (ULN), total bilirubin\<1.5×ULN;
10. Renal function: serum creatinine \<1.5×ULN;
11. Pulmonary function: FEV1\>50%, the percentage of DLCO (lung diffusion function) measured value and predicted value\>80% mild to moderate lung function impairment.
12. The patient has good compliance with the treatment and follow-up.

Exclusion Criteria:

1. There is evidence of distant metastasis (M1, AJCC 8th edition \[Rice et al., 2017\]);
2. There is pleural effusion, pericardial effusion or ascites that is not clinically controlled and requires repeated drainage or medical intervention (within 2 weeks before randomization);
3. Intolerance or resistance to the chemotherapy, targeted, and immunotherapy specified in the experimental protocol;
4. Have received radiotherapy and surgical treatment;
5. There were other active malignant tumors ≤ 2 years before enrollment, except for the specific cancers under study in this study and locally recurring cancers that have been cured (eg, resected basal cell or squamous cell skin cancer, superficial Bladder cancer, carcinoma in situ of the cervix or breast);
6. A history of interstitial lung disease, non-infectious pneumonia or uncontrolled systemic diseases, including pulmonary fibrosis, acute lung diseases, etc.;
7. Has suffered from other malignant tumors;
8. Subjects who have received other drug trials within the past month;
9. Pregnant or lactating women and women who refuse contraception during the treatment observation period;
10. People with a history of severe allergies or idiosyncratic physique;
11. Those with a history of severe lung or heart disease;
12. Refusal or inability to sign the informed consent to participate in the trial;
13. Drug or alcohol addicts;
14. Personality or mental illness, lack of capacity for civil conduct or limited capacity for civil conduct.",,,INTERVENTIONAL
NCT06517823,Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back Pain,Acute Low-back Pain,COMPLETED,"Inclusion Criteria:

* Agree to participate in the study and give written informed consent
* Patient with pain reported as moderate to severe intensity with ≥ 40 mm on the Visual Analog Scale (VAS).
* At least 4 points on the ""Douleur Neuropathique-4 items"" (DN-4) scale.
* Diagnosis of acute low back pain as a first-time episode or a previous episode 6 months before the enrollment day and lasting no more than 6 weeks.
* Women of childbearing potential under a medically acceptable method of contraception

Exclusion Criteria:

* Patients participating in another clinical trial involving an investigational treatment or participation in one within 4 weeks prior to study start
* Patients in whom the participation in the study may be influenced (employment relationship with the research site or sponsor, inmates, etc.)
* At medical discretion, a disease that affects prognosis and prevents outpatient management, for example, but not limited to: end-stage cancer, kidney, heart, respiratory or liver failure, mental illness or with scheduled surgical or hospital procedures
* History/presence of any disease or condition that, in the opinion of the Investigator, could pose a risk for the patient or confusing the efficacy and safety of the investigational product
* Patients in whom the study drug is contraindicated for medical reasons
* Patients with allergy or hypersensitivity to the active substance of the study drugs, related products or excipients (Etoricoxib of Cyanocobalamin)
* Pregnant women, women breastfeeding or planning a pregnancy during the conducting the study
* Significant history of gastrointestinal diseases (e.g., gastric ulcer, Crohn's disease, Ulcerative Colitis, etc.)
* Active opioid and/or NSAID treatment including COX-2 inhibitors, reported in the medical record within the last 72 hours of study entry.
* Patients with a history of congestive heart failure: NYHA II-IV.
* Concomitant use of strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, etc.).
* Patients with a history of alcohol or drug abuse in the last year
* Patients with a history of ischemic heart disease, peripheral artery disease, and/or cerebral vascular disease (including patients who have recently undergone coronary revascularization or angioplasty)
* Patients with a history of seizures, epileptic status and/or grand mal seizures
* History of chronic liver failure Child-Pugh A, B, and/or C
* History of acute renal failure (glomerular filtration rate \<30 ml/min/1.72 m2)
* Patient with a history of chronic pain associated with fibromyalgia, Paget's disease or bone pain induced by metastatic cancer
* Low back pain due to a history of major trauma in the past 12 months (e.g., vertebral fracture, post-traumatic spondylolisthesis) or due to a visceral disorder (e.g., dysmenorrhea, history of endometriosis).
* Patients with symptoms suggestive of COVID-19 infection (fever, cough, dyspnea) and/or contact in the last 14 days with a suspected or positive patient for COVID-19",,,INTERVENTIONAL
NCT00923481,"A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...","Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell",COMPLETED,"* INCLUSION CRITERIA:
* 3.1.1 Subjects must have histologically documented solid tumors: pheochromocytoma, follicular or papillary thyroid, colorectal, non-small cell lung (excluding squamous cell histology), hepatocellular, head and neck or renal cell origin, whose disease has progressed after any number of prior therapies or who have no acceptable standard treatment options.
* Patients with follicular or papillary thyroid cancer will be eligible if they have metastatic or unresectable, locally advanced disease which is refractory to, or not suitable for, I therapy.
* Diagnosis of malignancy must be confirmed by the Laboratory of Pathology at the Clinical Center, National Institutes of Health (NIH), prior to patient enrollment.
* 3.1.2 Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 10 mm with spiral computed tomography (CT) scan.
* 3.1.3 Life expectancy of greater than 3 months.
* 3.1.4 Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 (Karnofsky greater than or equal to 60%).
* 3.1.5 Subjects must have normal organ and marrow function as defined below:
* absolute neutrophil count greater than or equal to 1,500/mcL
* platelets greater than or equal to 100,000/mcL
* total bilirubin within less than or equal to 1.5 institutional upper limit of normal (ULN)
* aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase(SGOT),alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase(SGPT) less than or equal to 2.5 times ULN
* creatinine \< 1.5 times ULN

OR

* creatinine clearance greater than or equal to 60 mL/min/1.73 m\^2 for patients with creatinine levels greater than or equal to 1.5 times institutional upper limit of normal.
* 3.1.6 The effects of R935788 on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry, for the duration of study participation, and for 1 month after discontinuation of the study. Women of child bearing potential must have a negative pregnancy test in order to be eligible. Should a participant or a participant's partner become pregnant or suspect she is pregnant while participating in this study, the participant should inform the Research Team immediately.
* 3.1.7 Ability to understand and the willingness to sign a written informed consent document.
* 3.1.8 Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of R935788 in patients \< 18 years of age, children are excluded from this study, but may be eligible for future pediatric Phase I trials.
* 3.1.9 Patients with diagnosis of hypertension should have their blood pressure adequately controlled by medical therapy (adequate control of hypertension for the purposes of this trial is defined as systolic blood pressure \< 150 mmHg or diastolic pressure \< 90 mmHg).
* 3.1.10 Patients with head and neck cancer who are unable to swallow and who are gastrostomy tube (G-tube) dependent will have the tablets dissolved in water or orange juice followed by a free water or orange juice flush.

EXCLUSION CRITERIA:

* 3.2.1 Subjects who have had chemotherapy, biotherapy, or radiotherapy within 4 weeks prior to entering the study, or those who have not recovered from adverse events due to prior therapy.
* A time period of greater than or equal to 2 weeks must have elapsed since a patient was administered any investigational agent as part of a Phase 0 study (also referred to as an early Phase I study or pre-Phase I study where a sub-therapeutic dose of drug is administered) at the principal investigator's (PI's) discretion, and patients should have recovered from any toxicity from prior therapy to eligibility levels.
* 3.2.2 Patients must not have other current malignancies, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast.
* Patients who have undergone primary therapy for a prior diagnosis of cancer and are disease free for at least 3 years prior to study entry will be included in the trial.
* 3.2.3 Patients may not be receiving any other investigational agents.
* 3.2.4 Subjects with known brain metastases are excluded with the exception of those whose brain metastatic disease status has remained stable for at least 3 months since treatment of the brain metastases without steroids (except for maintenance replacement doses) or antiseizure medications.
* Patients cannot be taking enzyme-inducing anti-seizure medications (e.g., phenytoin, carbamazepine, phenobarbital, primidone, oxcarbamazepine); other seizure medications that are not considered enzyme-inducing would be permissible.
* 3.2.5 Because there is an unknown but potential risk for adverse events in nursing infants secondary to exposure to this agent, women who are breast feeding are ineligible for this study.
* 3.2.6 Patients receiving medications known to induce/inhibit cytochrome P450 3A4 (CYP3A4) will be excluded from this study.
* Patients who must initiate treatment with a CYP3A4 inhibitor while receiving R935788 will be carefully monitored.
* Inhibitors of CYP3A4 include but are not limited to:
* amiodarone,
* clarithromycin,
* erythromycin,
* imatinib,
* troleandomycin,
* ritonavir,
* indinavir,
* fluconazole,
* itraconazole,
* and ketoconazole.
* Patients should also avoid grapefruit and grapefruit juice during participation in the study.
* Patients will also be required to keep a study diary to record any side effects that occur during the study and any other medications taken.
* 3.2.7 Subjects with clinically significant illnesses which would compromise participation in the study, including, but not limited to: unstable or serious medical conditions (ongoing or active infection, symptomatic congestive heart failure \[AHA Class II or worse\], unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements) are excluded due to the possibility that the underlying condition may obscure the attribution of effect and adverse events with respect to the study medication and may limit study compliance.
* 3.2.8 Patients with hepatocellular cancer (HCC) may have underlying chronic infectious hepatitis as long as there is no evidence of hepatic failure and they meet the eligibility criteria.
* 3.2.9 Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with R935788.",,,INTERVENTIONAL
NCT02803281,Assessment of Patient Frailty Prior to Thoracic Surgery,"Lung Cancer, Esophageal Cancer",COMPLETED,"Inclusion Criteria:

* Patients with Esophageal or Lung Cancer who will undergo resectional surgery.

Exclusion Criteria:

* Patients undergoing diagnostic or staging procedures or pulmonary wedge excisions will be excluded.
* Patients unable to give informed consent",,,OBSERVATIONAL
NCT06110663,A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy,Non-Small Cell Lung Cancer,NOT_YET_RECRUITING,"Inclusion Criteria:

1. Men or women aged more than or equal to (≥) 18 years.
2. Patients histologically or cytologically confirmed with locally advanced or metastatic NSCLC.
3. Patients have previously received EGFR TKI treatment and had intolerance or disease progression by imaging recorded. Chemotherapy as systematic therapy is limited to no more than one prior line. Before randomization, all patients must provide imaging evidence of disease progression during or after the last treatment period. The patients are required to provide tumor biopsy tissue (required) and blood samples (optional) of disease progression after the last treatment of EGFR TKI, confirmed by central laboratory that there are EGFR sensitive mutations (deletion of exon 19 or L858R mutation) and T790M status (negative or positive) in tumor tissues and/or blood samples. Meanwhile, the tumor tissue should be c-MET positive confirmed by the central laboratory.
4. According to Recist1.1, at least 1 target lesion that should be measurable lesions without local treatment like irradiation or with definite progression after local treatment and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15mm)
5. ECOG performance status of 0-1with no deterioration within 2 weeks before enrollment.
6. Estimated life expectancy ≥three months.
7. Females of child bearing age should adapt adequate contraceptive measures and should not be breastfeeding from the signing of informed consent to 6 months after the last treatment of the study. Male patients should be willing to use barrier contraception (i.e., condoms) from the signing of informed consent to 6 months after the last treatment of the study.
8. Females must have a negative pregnancy test in 7 days prior to the date of randomization if of childbearing potential or must have evidence of non-childbearing potential by fulfilling any one of the criteria.
9. Signed and dated Informed Consent Form.

Exclusion Criteria:

1. Treatment with any of the following:

   1. Previous or current treatment with drugs targeting the c-MET/HGF pathway.
   2. Previous or under treatment with pemetrexed and platinum.
   3. Any cytotoxic chemotherapy, investigational agents, antitumor traditional Chinese Medicine and any other anticancer drugs for the treatment of advanced NSCLC within 14 days before the date of randomization; or requiring treatment with these drugs during the study.
   4. Any antitumor monoclonal antibody therapy within 28 days before the date of randomization.
   5. Local radiotherapy within 2 weeks of the date of randomization; receiving radiation to \> 30% of the bone marrow or with a wide field of radiation within 4 weeks before the date of randomization.
   6. Spinal cord compression or brain metastases (except for that being asymptomatic and stable for at least 4 weeks, not requiring steroids for at least 2 weeks prior to start of study treatment and with no obvious edema around the tumor focus by imaging examination).
   7. Currently receiving drugs known to prolong QT interval or may cause torsade de pointe; or requiring treatment with these drugs during the study.
2. Any unresolved toxicities from prior therapy greater than Grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0 with the exception of alopecia or neurotoxicity.
3. History of other primary malignancies.
4. Inadequate bone marrow reserve or organ function, as demonstrated by any of the following laboratory values:

   1. Absolute neutrophil count (ANC) \<1.5×109 / L
   2. Platelet count \<90×109 / L
   3. Hemoglobin \<90 g/L
   4. Total bilirubin (TBL) \> 1.5 × ULN or \> 3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases.
   5. One or both of Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) \> 2.5 × upper limit of normal (ULN) or \> 5 × ULN in the presence of liver metastases.
   6. Creatinine \> 1.5 × ULN concurrent with creatinine clearance \< 50 mL/min; confirmation of creatinine clearance is only required when creatinine is \> 1.5 × ULN.
   7. International normalized ratio (INR) \> 1.5, and partially activated prothrombin time (APTT) \> 1.5 × ULN.
   8. Serum albumin (ALB) \< 28 g/L
5. Any of the following cardiac criteria:

   1. Resting corrected QT interval (QTc) \> 470 ms obtained from electrocardiogram (ECG), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF).
   2. Left ventricular ejection fraction (LVEF) ≤ 50%.
6. Severe, uncontrolled or active cardiovascular diseases.
7. Diabetes ketoacidosis or hyperglycemia hypertonic occurring within 6 months before the date of randomization, or the glycosylated hemoglobin value ≥ 7.5% in the screening period.
8. Severe or poorly controlled hypertension.
9. Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Grade B or more severe cirrhosis.
10. Other moderate or severe lung diseases that may interfere with the detection or treatment of drug-related pulmonary toxicity or may seriously affect respiratory function.
11. Women who are breastfeeding or pregnant or planned to be pregnant during the study period.
12. History of hypersensitivity to any active or inactive ingredient of HS-10241/Almonertinib/ cisplatin/carboplatin/pemetrexed or to drugs with a similar chemical structure or class to HS-10241/Almonertinib/cisplatin/carboplatin/pemetrexed.
13. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
14. Any disease or condition that, in the opinion of the investigator, would compromise the safety of the patient or interfere with study assessments.",,,INTERVENTIONAL
NCT01687738,Lung Cancer Surgery: Decisions Against Life Saving Care - The Intervention,Non-small Cell Lung Cancer,COMPLETED,"Inclusion Criteria:

1. Age 21 years or greater;
2. A probability of 60% or higher of a lung lesion being malignant as calculated by a Bayesian algorithm using clinical and radiographic characteristics or biopsy proven disease; and
3. The patient has been clinically classified as having stage I or II disease.

Exclusion Criteria:

1. incarceration / ward of the state status,
2. Severe cognitive impairment. If a patient meets the inclusion criteria but is consistently unable to comprehend survey questions during the interview process, we will exclude that patient from the overall study.
3. absolute contraindications by pulmonary function testing (FEV-1 \< 25% of predicted)
4. Non-English speaking. Hispanic patients represent less than 4 percent of lung cancer patients in North Carolina restricting our ability to document an intervention effect.",,,INTERVENTIONAL
NCT00752206,A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung,Osteosarcoma,TERMINATED,"Inclusion Criteria:

* Patient had recurrence of osteosarcoma, localized to the lungs, had complete surgical removal of all lung nodules are eligible for enrollment.
* Patient with suspected recurrence of osteosarcoma but who has not had surgery is eligible for enrollment but will not be randomized to receive study medication until deemed fully eligible following surgical removal of all lung nodules.
* Patient had histological confirmed diagnosis of osteosarcoma of the recurrent sample.
* Patient had recurrence of osteosarcoma in the lung following standard therapy including: adriamycin, cisplatin, ifosfamide and methotrexate.
* Patient is ≥ 15 and \< 75 years of age.
* Weight ≥ 34 kg.
* ECOG performance score of 0-2.
* Adequate bone marrow function.
* Adequate renal function.
* Adequate hepatic function.
* Adequate cardiac function.
* Women of childbearing potential must have had a negative pregnancy test (urine or serum) ≤ 7 days prior to enrollment, and willingness to use an acceptable method of contraception during participation in the study and for 3 months after the last dose.
* Randomization must occur ≤ 6 weeks after complete surgical resection.
* Patient or legal guardian has signed informed consent.

Exclusion Criteria:

* Presence of metastatic disease in other locations in addition to the lung.
* Disruption of the lung pleura by tumor.
* Paget's disease.
* Patient currently using, or has previously used CYP3A4 inducers or inhibitors within 2 to 14 days prior to the initiation of oral therapy.
* Known hypersensitivity to other Src/Abl non-receptor kinase inhibitors.
* Evidence of interstitial lung disease.
* Any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.
* Myocardial infarction within one year prior to study entry.
* Bleeding diathesis, resulting in symptomatic bleeding.
* Patient is pregnant or nursing/breast-feeding.
* Patient received chemotherapy, biological or investigational agent ≤ 28 days prior to enrollment.
* Patient experiencing unresolved toxicity ≥ CTCAE grade 2 (except alopecia) from previous agents.",,,INTERVENTIONAL
NCT05968898,Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES,"Lung Cancer, Pulmonary Nodule, Solitary",RECRUITING,"Inclusion Criteria:

1. Male or female, aged 35-89 years
2. Scheduled to be evaluated at a UPHS PN clinic
3. Newly discovered solid or part-solid indeterminate PN 8-30mm in maximal diameter on CT imaging within 60 days of index clinic visit
4. Chest CT imaging meeting the technical requirements for compatibility with Optellum Virtual Nodule Clinic software

Exclusion Criteria:

1. Chest CT imaging with discrete mediastinal or hilar lymphadenopathy by CT size criteria (\>10mm in maximal short-axis diameter on axial CT images)
2. PNs with popcorn calcification (consistent with benign etiology)
3. Pure ground-glass subsolid PNs (may be associated with lower risk of clinically significant malignancy)
4. PN previously seen on CT imaging \>60 days prior to most recent CT
5. More than one indeterminate PN 8-30mm in maximal diameter
6. History of lung cancer
7. History of active cancer within the previous 5 years
8. Presence of a thoracic implant that impedes PN visualization",,,INTERVENTIONAL
NCT05526573,Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions,"Lung Cancer, Lung; Node, Lung Diseases, Lung TB, Lung Adenocarcinoma, Lung Transplant Rejection",RECRUITING,"Inclusion criteria:

* Candidate for a diagnostic procedure for a new peripheral lung lesion or re-biopsy;
* Tissue sampling of the peripheral lesion performed only with UB;
* The patient's ability to understand the individual characteristics and consequences of the clinical study;
* Males and females of any ethnicity;
* Subjects who have given their informed consent to use their clinical data for research purposes.

Exclusion criteria:

* Inability to give informed consent or understand its contents;
* Unavailability of tomographic imaging;
* Failure to use RP-EBUS or fluoroscopic guidance during the procedure;
* Failure to use R.O.S.E. by the pulmonologist or pathologist during the procedure;
* Tissue sampling on the same peripheral lesion using an instrument of a different caliber in replacement or in association;
* Any other significant illness or disorder that, in the investigator's opinion, may put the patient at risk due to study participation.",,,OBSERVATIONAL
NCT00956852,Study on Systemic and Airway Cytokines and Oxidative Stress in Lung Cancer Patients Undergoing Surgery,Lung Cancer,TERMINATED,"Inclusion Criteria:

* Histologically or cytologically confirmed early-stage non-small cell lung cancer undergoing curative surgical lung resections.
* Life expectancy \> 12 weeks.

Exclusion Criteria:

* Respiratory failure requiring use of supplemental oxygen therapy.",,,OBSERVATIONAL
NCT04743752,Obstructive Sleep Apnea Influences Efficacy of PD-1-Based Immunotherapy Against Non-Small Cell Lung Cancer,"Obstructive Sleep Apnea, Non-small Cell Lung Cancer",RECRUITING,"Inclusion Criteria:

1. Histologically or cytologically confirmed, advanced NSCLC
2. Participants with no prior treatment for advanced NSCLC
3. Measurable disease as defined by RECIST v1.1
4. Eligible to receive first-line treatment including PD-1 antibody
5. Adequate hematologic and end organ function

Exclusion Criteria:

1. Severe infection within 4 weeks prior to recruitment.
2. Significant organ dysfunction or other serious diseases.
3. Previous or current OSA related treatment, including oral appliance, surgery, mechanical ventilation therapy.
4. Illness or condition that interferes with the participant's capacity to understand, follow and/or comply with study procedures.",,,OBSERVATIONAL
NCT02862587,Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer,"Precision Cells, Chemotherapy, Advanced Lung Cancer",UNKNOWN,"Inclusion Criteria:

* Age 18\~65 years old, male or female;
* Life expectancy≥6 months;
* ECOG score: 0-3;
* Advanced Malignancies (lung cancer) were diagnosed by pathological or clinical physicians;
* Enough venous channel, no other contraindications to the separation and collection of white blood cells;
* Laboratory examination: white blood cell≥3 x 10\*9/L, blood platelet count≥60 x 10\*/L,hemoglobin≥85g/L; lymphocyte count≥15%, total bilirubin≤100 mol/L; ALT and AST less than five times of the normal level; serum creatinine less than 1.5 times of the normal level;
* Signed informed consent;
* Women of child-bearing age must have evidence of negative pregnancy test and be willing to practice birth control after 2 weeks following the cells transfusion.

Exclusion Criteria:

* Expected Overall survival \< 6 months;
* Patients with uncontrolled hypertension (\>160/95mmHg), unstable coronary disease (uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (\> Class II, NYHA), or myocardial infarction within 6 months;
* Other serious diseases: nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc;
* Other drugs, or other biological treatment,chemotherapy or radiotherapy are performed within a month;
* Unable or unwilling to provide informed consent, or fail to comply with the test requirements.",,,INTERVENTIONAL
NCT05906329,Low-dose Radiotherapy Combined With Conventional Fractionated Radiotherapy in Lung Cancer After Immunotherapy Resistance,Cancer Patients,UNKNOWN,"Inclusion Criteria:

* 1\. Patients are able to understand the informed consent form, voluntarily participate and sign the informed consent form.

  2\. Age range from 18 to 65 years old, regardless of gender.

  3\. ECOG level 0-1; Expected life\>6 months.

  4\. At least get into a liquid diet.

  5\. No history of severe allergies.

  6\. Hemoglobin ≥ 100 g/L, WBC ≥ 3.5 x10\~9/L, neutrophils ≥ 1.8 x10\~9/L, platelets ≥ 10 x10\~9/L; AST and ALT ≤ 2.5 × normal upper limit, AKP ≤ 2.5 × normal upper limit.

  7\. Non small cell lung cancer (adenocarcinoma, large cell carcinoma, squamous carcinoma, adenosquamous carcinoma, sarcomatoid carcinoma) confirmed by cytology or histology.

  8\. Complete clinical data.

  9\. ≤ 10 primary and regional metastatic lymph nodes and distant metastatic lesions, and ≤ 5 organ metastases.

  10\. Malignant tumor patients with immune therapy resistance (evaluated after 6-8 weeks of treatment and no improvement in clinical symptoms) without standard treatment options.

  11\. There are measurable primary lesions, regional lymph node metastasis, and distant metastatic lesions.

Exclusion Criteria:

* 1\. Missing key patient information (pathological diagnosis, radiation dose, imaging examination, previous treatment plans, etc.).

  2\. Refusal or lack of cooperation in research.

  3\. Patients who have participated in other clinical studies/trials within three months.

  4\. Patients with brain metastases.

  5\. The researcher determines that there are any patients who are not suitable to participate in the study.

  6\. Accompanied by severe infections.

  7\. Serious liver disease (such as cirrhosis), kidney disease, respiratory disease or chronic system diseases such as uncontrollable diabetes and hypertension; Patients who cannot tolerate radiation therapy.

  8\. Previous occurrence of immune related toxic side effects (immune myocarditis, pneumonia, etc.).

  9\. Previous history of radiation therapy.",,,INTERVENTIONAL
NCT04039529,"Novel Guidance Device for Image Fusion and Needle Guidance in Lung, Liver or Kidney Biopsy","Liver Biopsy, Lung Biopsy, Kidney Biopsy",WITHDRAWN,"Inclusion Criteria:

* all patients between the ages of 18 and 80 years old at time of procedure who are pre-scheduled for a lung, kidney, or liver biopsy.

Exclusion Criteria:

* any patient who was under the age of 18 or over the age of 80 at time of the procedure or who does not wish to volunteer for the study.",,,INTERVENTIONAL
NCT02600481,Impacts of Different Pressure Pneumoperitoneum on Myocardial and Pulmonary Injuries After Robot-assisted Surgery,"Prostatic Neoplasms, Urinary Bladder Neoplasms",UNKNOWN,"Inclusion Criteria:

* Patients who are scheduled to undergo Robot-assisted radical prostatectomy or other robot-assisted urological surgeries last longer than 3 hours
* Patients who are classified as American Society of Anesthesiologists（ASA）I and II
* Patient's preoperative troponin T(TnT) level is normal

Exclusion Criteria:

* Patients with preoperative cardiopulmonary dysfunction who can not understand prolonged surgeries in the Trendelenburg position：severe pulmonary dysfunction or New York Heart Association(NYHA) classification is Ⅲ-Ⅳ.
* Body Mass Index\>30.
* Any intraoperative situation as follows：1. Any cause to cancel operation or change robot-assisted surgery to open surgery 2. Intraoperative cardiovascular accidents.",,,INTERVENTIONAL
NCT02016209,Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer,Non Small Cell Lung Cancer,UNKNOWN,"Inclusion Criteria:

1.Histological or cytological diagnosis of NSCLC of Stage Ⅱ B and IIIA .

2.18 years or older 3.Performance Status 0 to 2; 4.Appraisable disease; 5.patients can tolerant chemotherapy; 6.Total bilirubin 1.5 x upper limit of normal (ULN); 7.Creatinine clearance 60ml/min (calculated according to Cockcroft-gault formula).

Exclusion Criteria:

1.Any systemic anticancer treatment for NSCLC；2.Local radiotherapy for NSCLC；3.In this study within five years prior to the start of treatment with other than NSCLC patients with other cancers.4.Any instability in systemic disease; 5.Allergic to paclitaxel or Platinum;6.Pregnant or lactating women;7.Other researchers believe that does not fit into the group",,,INTERVENTIONAL
NCT03457506,Intra-individual Comparison of Conventional and Digital PET/CT Scanners,"Breast Cancer, Lung Cancer, Esophageal Cancer, Miscellaneous Neoplasm",COMPLETED,"Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

* referred to Isala for a clinically indicated FDG-PET/CT scan
* suspected or proven lung cancer, esophageal cancer, breast cancer or miscellaneous cancer, either as a primary diagnosis or follow-up study
* signed informed consent

Exclusion criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study:

* age \< 18 years
* incapacitated adults
* prisoners
* pregnant patients
* unable to undergo two consecutive PET/CT scans",,,INTERVENTIONAL
NCT00481624,Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia,Anemia,WITHDRAWN,"Inclusion Criteria:

* Histologically confirmed small cell or non small cell lung cancer
* Stage III or Stage IV lung cancer
* Platinum containing chemotherapy induced anemia (\< 10 g/dl Hb)
* Cancer related anemia (\<10 g/dl Hb) at time of initiation of chemotherapy
* ECOG performance status of 0,1, or 2
* Informed consent
* Age\>18
* Expected to receive platinum based outpatient chemotherapy for at least nine weeks

Exclusion Criteria:

* Pregnant women
* Intolerance to epoetin alfa or parenteral iron
* More than 2 cycles of the planned platinum chemotherapy at time of enrollment
* Chronic GI bleed (\> than 4 weeks positive hemoccult or gastroccult)
* Ferritin \> 500 mg/dl
* Anemia due to other causes than cancer or chemotherapy
* Previous parenteral iron therapy
* Uncontrolled hypertension (systolic BP \> 160, diastolic \> 100 mmHg)",,,INTERVENTIONAL
NCT06897735,Exploratory Study of Inhaled Afatinib Dimaleate PK Profile,"Lung Cancer, Oral Cancer, Melanoma",NOT_YET_RECRUITING,"Inclusion Criteria:

* Healthy male and female volunteers aged 21 to 55 years
* Body mass index (BMI) from 18.5 to 30.0 kg/m²
* Smokers or people who use e-cigarettes or vapes
* No history of serious lung disease or respiratory disorders
* No history of EGFR-targeted therapy or chemotherapy
* Ability to give informed consent and comply with study procedures

Exclusion Criteria:

* Pregnancy or lactation. (for female participants - 2 negative tests 10 days and 3 days before the start of the study)
* Significant cardiovascular, hepatic, renal or neurological disorders. (ECG 30 days or earlier before the start of the study)
* Recent use of any study drug (within 30 days) or prescription drugs that may affect the metabolism of afatinib
* Known hypersensitivity to afatinib, its salts or derivatives of afatinib or related compounds
* Рarticipation in other studies",,,INTERVENTIONAL
NCT06936735,Phase I Study of HS-20108 in Participants With Advanced Solid Tumors,Advanced Solid Tumor,NOT_YET_RECRUITING,"Inclusion Criteria:

1. Men or women aged more than or equal to (≥) 18 years.
2. Participants with pathologically confirmed advanced solid tumors.
3. At least one measurable lesion in accordance with RECIST 1.1
4. Fresh or archival tumor tissue available for submission.
5. Eastern Cooperative Oncology Group (ECOG) performance status: 0\~1.
6. Estimated life expectancy \>12 weeks.
7. Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit.
8. Females must have evidence of non-childbearing potential.
9. Signed and dated Informed Consent Form.

Exclusion Criteria:

1. Treatment with any of the following:

   Having received cytotoxic chemotherapy agents, investigational drugs, Chinese medicine treatment with anti-tumor indications, or other anti-tumor therapy (including endocrine therapy, molecular targeted therapy, or biotherapy) within 14 days before the first dose of study treatment.

   Having received macromolecular anti-tumor drug therapy (including immunotherapy, such as monoclonal antibody drugs and bispecific antibody drugs) within 28 days before the first dose of study treatment.

   Local radiotherapy for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose.

   Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of study drug.
2. Inadequate bone marrow reserve or serious organ dysfunction.
3. Uncontrolled pleural effusion or ascites or pericardial effusion.
4. Known and untreated, or active central nervous system metastases.
5. Active autoimmune diseases or active infectious disease
6. Known to have interstitial pneumonia or immune pneumonia
7. History of severe allergic reaction, serious transfusion reactions or Allergy to any component of HS-20108
8. The subject who is unlikely to comply with study procedures, restrictions, or requirements judged by the investigator.
9. The subject whose safety cannot be ensured or study assessments would be interfered judged by the investigator.
10. Pregnant women, breastfeeding women or woman who has a child-bearing plan during the study.
11. History of neuropathy or mental disorders, including epilepsy and dementia.",,,INTERVENTIONAL
NCT00100633,Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People,"HIV Infections, Hepatitis B",COMPLETED,"Inclusion Criteria for HIV Infected Participants:

* HIV-1 infection
* If receiving combination antiretroviral therapy (ART), must have been on ART for at least 3 months prior to study entry. Patients who anticipate a change in treatment (either initiating ART or stopping ART) in the next 7 months are not eligible.
* CD4 count of 250 cells/mm3 or greater
* Negative HBsAb, HBsAg, and HBcAb
* Willing to use acceptable forms of contraception while on study treatment and for 24 weeks after study treatment has ended

Inclusion Criteria for HIV Uninfected Participants:

* HIV uninfected
* Negative HBsAb, HBsAg, and HBcAb
* Willing to use acceptable forms of contraception while on study treatment and for 24 weeks after study treatment has ended

Exclusion Criteria for All Participants:

* Cancer. Participants with squamous cell or basal cell skin cancer are not excluded.
* Autoimmune disease
* Immunosuppressive medications. People who use or have used corticosteroid nasal sprays are not excluded. People who have received fewer than 2 weeks of systemic corticosteroids with the last dose over a month prior to study entry are not excluded.
* Any medical or psychiatric condition or occupational responsibilities that may interfere with the study
* Immunomodulator or investigational agent therapy within 30 days prior to study entry
* Allergy/sensitivity to study drugs or their formulations, including thimerosal
* Current drug or alcohol use that, in the opinion of the investigator, would interfere with the study
* Active hepatitis C virus infection, as indicated by serum antibodies to HCV AND detectable HCV RNA in plasma
* Blood clotting abnormalities
* Any other condition that, in the opinion of the investigator, might interfere with the study
* Pregnancy or breastfeeding",,,INTERVENTIONAL
NCT03979170,Patient-derived Organoids of Lung Cancer to Test Drug Response,"Lung Cancer, Organoid",RECRUITING,"Inclusion Criteria:

* Histologically proven lung cancer
* Age ≥ 18
* Written informed and signed consent
* Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour

Exclusion Criteria:

* Less than 18 years of age
* Not able to give informed consent (language, intellectual capacities, etc.)
* Not accessible to biopsy and/or surgery sample
* Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.",,,OBSERVATIONAL
NCT04819997,A Nurse-Led Intervention for Fear of Progression in Advanced Cancer,"Advanced Lung Carcinoma, Metastatic Malignant Female Reproductive System Neoplasm, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8",ACTIVE_NOT_RECRUITING,"Inclusion Criteria:

1. Patients with stage III or IV gynecologic (GYN) or lung cancer
2. At least 3 months from initial diagnosis
3. Score \>= 34 on the Fear of Progression-short form (SF) questionnaire

Exclusion Criteria:

1. Severe mental illness (e.g. psychosis)
2. Hospice enrolled
3. Non-English speaking",,,INTERVENTIONAL
NCT05204628,A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib,Non-small Cell Lung Cancer,NOT_YET_RECRUITING,"Inclusion Criteria:

1. Patients must be 18-75 years-of-age;
2. Patients with Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB and IIIC not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive where ALK status is determined by the NMPA-approved (for use in China) Ventana (D5F3) immunohistochemistry (IHC) test or FISH or PCR or NGS, Sufficient tumor tissue available to perform ALK status is required if not determined.
3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to 2;
4. Life expectancy of at least 12 weeks;
5. Ability to swallow and retain oral medication;
6. Adequate organ system function, defined as follows:

   1. Absolute neutrophil count (ANC) ≥1.5 x 109/L; Platelets ≥100 x 109/L; Hemoglobin ≥9 g/dL (≥90 g/L)
   2. Total bilirubin ≤1.5 times the upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 \*ULN if no liver involvement or ≤5 \* ULN with liver involvement.
   3. Creatinine \< 1.5 \*ULN. If \>1.5 \* ULN, patient may still be eligible if calculated creatinine clearance \>50 mL/min (0.83mL/s) as calculated by the Cockcroft-Gault method.
7. No prior systemic treatment for advanced or recurrent NSCLC (Stage IIIB and IIIC not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC
8. Tumor Requirements: At least 1 extracranial measurable target lesion per RECIST v. 1.1 that has not been previously irradiated.
9. Serum pregnancy test (for females of childbearing potential) negative at screening.
10. Ability to understand the nature of this trial and give written informed consent.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from study entry:

1. Patients with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in PFS and OS for the current NSCLC).
2. Any GI disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post-major bowel resection ;
3. Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV) or hepatitis C virus (HCV) (eg, in case of known HBsAg or HCV antibody positivity), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness;
4. Clinically significant vascular (both arterial and venous) and non-vascular cardiac conditions, (active or within 3 months prior to enrollment), which may include, but are not limited to:

   1. Arterial disease such as cerebral vascular accident/stroke (including Transient Ischemic Attack -TIA), myocardial infarction, unstable angina;
   2. Venous diseases such as cerebral venous thrombosis, symptomatic pulmonary embolism;
   3. Non-vascular cardiac disease such as congestive heart failure (New York Heart Association Classification Class ≥ II), second-degree or third-degree AV block (unless paced) or any AV block with PR \>220 msec; or ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, bradycardia defined as \<50 bpm (unless patient is otherwise healthy such as long-distance runners, etc.), machine-read Electrocardiogram (ECG) with QTc \>470 msec, or congenital long QT syndrome;
5. Patients with predisposing characteristics for acute pancreatitis according to investigator judgment (eg, uncontrolled hyperglycemia, current gallstone disease) in the last month prior to randomization;
6. History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis;
7. Concurrent use of known strong CYP3A4 inhibitors and inducers (consult the sponsor if in doubt whether a food or a drug falls into any of the above categories) within 7 days prior to the first dose of XZP-3621 or crizotinib.
8. Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation;
9. Pregnant female patients; breastfeeding female patients;
10. History of organ transplant;
11. Co-administration of anti-cancer therapies other than those administered in this study;
12. Baseline QTc\>470ms ;
13. History of hypersensitivity to any of the additives in the XZP-3621 or crizotinib drug formulation;
14. Any psychological condition that potentially hampers compliance with the study protocol requirements or follow-up procedures; this condition should be discussed with the participant before study entry.",,,INTERVENTIONAL
NCT00312728,A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT),"Non-Small Cell Lung Cancer, Brain Neoplasms",COMPLETED,"Inclusion Criteria:

* Signed informed consent
* Histologically or cytologically confirmed NSCLC except for squamous cell carcinoma
* Treated brain metastases without evidence of progression or hemorrhage after treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period
* Appropriateness for first- or second-line systemic therapy for advanced NSCLC
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Age ≥ 18 years
* For women of childbearing potential and sexually active males, use of an accepted and effective method of contraception (e.g., hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study

Exclusion Criteria:

* Brain biopsy/neurosurgical procedure performed within 3 months prior to Day 1
* Progressive neurologic symptoms
* Active malignancy other than lung cancer
* Current, recent, or planned participation in an experimental drug study
* Prior treatment with an investigational or marketed agent that acts by anti-angiogenesis mechanisms
* Gross hemoptysis within 3 months prior to Day 1
* Inadequately controlled hypertension
* Unstable angina or New York Heart Association Grade II or greater congestive heart failure (CHF)
* Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1
* Myocardial infarction within 6 months prior to Day 1
* Stroke within 6 months prior to Day 1
* Active symptomatic peripheral vascular disease within 6 months prior to Day 1
* History of significant vascular disease
* Evidence of bleeding diathesis or coagulopathy
* Known hypersensitivity to any components of bevacizumab
* Inadequate organ function
* Serious non-healing wound, ulcer, or bone fracture
* Urine protein/creatinine (UPC) ratio of ≥ 1.0
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, or anticipation of need for major surgical procedure during the course of the study
* Pregnancy or lactation
* Known evidence of disseminated intravascular coagulation (DIC)
* Active infection or fever \> 38.5°C within 3 days prior to Day 1
* Any other medical condition (including mental illness or substance abuse) deemed by the clinician to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results",,,INTERVENTIONAL
